

# Subject Index

## A

### ACANTHOSIS NIGRICANS

and antibodies against insulin receptor, 149

### ACARBOSE

and carbohydrate absorption in man, 951-954

### ACETALDEHYDE

and insulin and glucagon secretion in perfused rat pancreas, 705-708

### ACETATE

and insulin and glucagon secretion in perfused rat pancreas, 705-708

### ACETAZOLAMIDE

and furosemide  
and renal insulin uptake, 930-933

### ACETOACETATE

renal clearance of, in diabetic ketoacidosis, 510-517

### ACETONE

renal clearance of  
in diabetic ketoacidosis, 510-517

### ACETYLCHOLINE

and electrical activity in perfused isolated mouse islets of Langerhans  
glucose effects compared with, 558-561

### N-ACETYLGLUCOSAMINIDASE

in diabetic and normal serum, 115-117

### ACID

hyaluronic  
in glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393-395

arachidonic  
platelet metabolism in diabetics and, \*44-47

13-azaprostanic  
and inhibition of arachidonic-acid-induced platelet aggregation in diabetics and nondiabetics, \*46-47

organic  
during recovery phase of diabetic ketoacidosis, 310-313

### ACID-BASE BALANCE

and ketone bodies, 517

### ACID-ETHANOL EXTRACTION

and insulin content in insects and annelids, 70-75

### ACIDOSIS, HYPERCHLOREMIC

in diabetes, 785-786

### ACROGMEGALY

and insulin binding by erythrocytes and monocytes, 896-901

### ACTH

plasma cortisol response in hyperkalemic diabetics, 338

### ADENINE NUCLEOTIDES

in erythrocytes from diabetics with ketoacidosis  
insulin therapy and, 346-352

### ADENOMAS

from rats treated with nicotinamide and streptozotocin  
insulin release in vitro from, 302-308

### ADENOSINE TRIPHOSPHATE

release from blood platelets after incubation with soluble immune complexes from diabetic sera, 575-578

### ADIPOCYTES

isolated rat  
insulin binding studies of, 196-201  
insulin-induced receptor loss and internalization in, 746-752  
prostacyclin production, 163-166  
lipogenesis  
immunoglobulin G stimulation of, 1068-1071  
from obese rodents  
insulin resistance studies of, 151  
size  
serum insulin and, 19

### ADIPOSE TISSUE. See also Adipocytes

rat  
effects of streptozotocin diabetes and insulin on cyclic AMP phosphodiesterase and protein activator in, 372-375

### ADRENAL MEDULLA

impaired activation during insulin-induced hypoglycemia in diabetics with autonomic neuropathy, 626, 632

### $\beta$ -ADRENERGIC BLOCKADE

glucose recovery during, 261-263

### $\alpha$ -ADRENERGIC RECEPTORS

at pancreatic islet cells, 172-174

### $\beta$ -ADRENERGIC RECEPTORS

in rat pancreatic islet cells, 172-174

### AGE

and blood platelet aggregation in diabetics, 488  
and capillaries of skeletal muscle in diabetics, 328  
and cardiovascular disease mortality in normoglycemics, borderline diabetics, and diabetics, \*50-52  
of diabetes onset  
by race and sex in Allegheny County Insulin-Dependent Diabetes Mellitus Registry, 280, 281-283  
of diabetic and nondiabetic Pima Indians and Caucasians  
in plasma protein excretion study, 658  
and diabetogenic effects of streptozotocin in mice, 718-722  
and hyperinsulinism and obesity, 14-18  
of hypoglycemia patients in glucose tolerance tests and mixed meals study, 466  
in insulin resistant non-insulin-dependent diabetics study, 991  
and proinsulin and insulin secretion in isolated rat islets, 77-82  
in rural-urban diabetes prevalence study in Polynesians, 47, 48, 49  
and serum glycosidase activity in diabetics and normals, 115-117

### ALBUMIN

in dermal capillary basement membrane  
in insulin-dependent diabetics, 275-278  
in kidney basement membranes and diabetic nephropathy, other kidney diseases, and normal kidney, 843-845

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

\* This index covers all reading matter in Volume 30 of DIABETES except the abstracts of papers presented at the 41st Annual Meeting of the American Diabetes Association. Entries marked with an asterisk indicate material that appeared in Supplement 2, Proceedings of a Conference on Diabetes and Atherosclerosis.

- selective extravascular escape into cerebral cortex of diabetic rat, 500-503
- ALBUMINURIA**  
response to exercise  
and continuous subcutaneous insulin infusion in insulin-dependent diabetic men, 818-822
- ALCOHOL FLUSH**  
chlorpropamide-induced  
plasma acetaldehyde as indicator of, 788-790
- ALDOHEXOSES**  
intestinal absorption in streptozotocin-diabetic rats, 569
- ALDOSE REDUCTASE INHIBITORS.** See *Arestatin*
- ALDOSTERONE**  
deficiency  
and glucose-induced hyperkalemia, 335-339
- ALLOGRAFTS**  
rejection  
and passenger leucocytes, 242-246
- ALLOXAN**  
diabetogenic effects in mice  
age and, 719  
and inhibition of islet superoxide dismutase, 235-240
- ALLOXAN DIABETES**  
in dogs  
hypersomatostatinemia of insulin deficiency and high plasma free fatty acid levels and, 358-360  
and effect of islet-activating protein in dogs, 430-434  
in rabbits  
atherosclerosis incidence studies in, \*55  
and energy metabolism in peripheral nerve axons and Schwann cells, 967-974  
and rat hepatic fructose 2,6-bisphosphate levels, 1062-1064  
in rats  
coagulation studies in, \*36-37  
and intestinal glucose uptake, 247-255
- ALRESTATIN**  
and diabetic peripheral neuropathy, 459-463  
and polyol levels in rats, 459
- AMERICAN DIABETES ASSOCIATION**  
Annual Meetings  
forty-first, 5, xx; 365, 756, 796
- Feasibility Grant Program, 795  
Lilly Award Nominations, 795  
Necrology, 3, 1x  
New Members, 2, xiv; 5, xx; 8, xi; 9, v; 86, 538, 795, 1076  
News of Affiliate Associations, 365, 1076  
Organization Section, 2, xiv; 3, ix; 5, xx; 8, xi; 9, v; 86, 365, 538, 795-796, 1076  
Research and Development Award, 795  
applications, 86  
Research Grants, 86, 1076  
Reviewers of Manuscripts, 87-88
- AMINO ACIDS**  
dicarboxylic  
prevention of insulin aggregation by, 83-85  
release from muscle to liver and hypoglycemia in pregnancy, 549  
transport in fibroblasts from maturity-onset diabetics and unaffected family members, 944
- AMYLASE**  
secretion in rat pancreas  
insulin and insulin secretagogues and activation of, 396-401
- ANALGESICS**  
in clinical trial of aldose reductase inhibition in diabetic neuropathy, 460-463
- ANGIOGRAPHY**  
and elevated insulin responses to oral glucose in ischemic heart disease, \*54
- ANGIOTENSIN II**  
infusion in hyperkalemic diabetics, 337-338
- ANGIOTENSIN-CONVERTING ENZYME**  
in endothelial cells of large and small vessels, \*25
- ANILINE**  
and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701
- ANION GAP**  
unmeasured  
in diabetic ketoacidosis, 781-785
- ANNELIDS**  
insulin content, 70-75
- ANOXIA**  
effects on phosphorylase activity and glucose metabolism by skeletal muscle of genetically obese-diabetic mice, 214-215
- ANTIBODIES**  
against insulin receptor, 149  
and glucose uptake by cultured human fibroblasts, 523-528  
antithyroid  
and insulin-dependent diabetes and autoimmune thyroid disease, 1060  
to insulin  
and insulin action studies in diabetics, 652, 654  
and insulin resistance, new insulin analogues and, 519-522  
and <sup>125</sup>I-insulin, 5  
to insulin, in sera from diabetic patients and soluble immune complexes effect on platelet aggregation and ATP release, 575-578  
islet cell  
induced in mice, 30-38  
islet-cell complement-fixing  
from diabetics, insulin release and, 1051-1056  
islet-cell-specific  
and insulin release, 231-234  
lymphocytotoxic  
and histocompatibility antigens in juvenile-onset diabetics, 26-29  
monoclonic of lymphocyte hybrid cell lines  
reaction with rat islet cell membrane antigens, 226-230  
to nucleic acids  
in insulin-dependent diabetics and unaffected relatives, 873-874
- ANTIGEN-ANTIBODY COMPLEXES**  
and vascular injury, \*2  
response to pneumococcal immunization  
in diabetics and normals, 119-121
- ANTIGENS.** See also Histocompatibility antigens; HLA-DR4 antigens  
factor VIII  
in endothelial cells of large and small blood vessels, \*25  
of rat islet cell membrane  
production of monoclonal antibodies reacting with, 226-230
- ANTILYMPHOCYTE SERUM THERAPY**  
and blood donor-specific pretreatment  
pancreatic islet allograft survival in rats and, 947-950
- ANTISERUM**  
anti-platelet  
and blocking of atherosclerosis, \*3  
and immunologic activity of synthetic insulins, 265-266  
to insulin  
and wound healing in mice, 407-410  
specificity

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# SUBJECT INDEX 1981

- in radioimmunoassay and affinity chromatography of somatostatin-like activity, 472
- AORTA**  
chicken  
insulin-induced lesions of, \*55  
rabbit  
comparison of two types of reaction to arterial wall injury in, \*11-12  
and endothelial injury and atherogenesis, \*2-3  
mechanical injury and formation of atherosclerotic lesions in, \*8-9
- APOC-III**  
diet and degree of sialylation of, 530-533
- APOLIPOPROTEINS**  
ApoC-III  
diet and degree of sialylation of, 530-533  
and high-density lipoprotein metabolism in insulin-dependent diabetes, \*84-85
- APOPROTEINS**  
and lipoprotein metabolism in atherosclerosis, \*60-65, \*83
- ARACHIDONIC ACID**  
and atherogenesis, \*3  
platelet metabolism of, in diabetes, \*44-47
- ARGININE**  
high doses in neonatal rat model for non-insulin-dependent diabetes  
insulin and glucagon responses to, 591-592, 594  
-loading tests  
and effect of islet-activating protein in normal dogs, 431-432, 433  
-stimulated insulin release in triphenyltin fluoride-treated rabbits, 1016-1017  
vincristine and, 539-544
- ARTERIES**  
collagen and fibronectin  
and diabetic serum and growth hormone, \*16  
coronary  
in acute myocardial infarction, \*39  
from cholesterol-fed miniature swine, \*60, \*61  
cultured monkey cells  
insulin effects on, \*55-56  
and endothelial injury, \*2-4  
immunological injury to  
and atherosclerosis, \*9  
injury  
atherogenesis and, \*8-12  
and herpesvirus-induced atherosclerosis in chickens, \*30-31  
lipid metabolism  
in streptozotocin-diabetic rats, \*55  
stiffening in diabetes, \*101
- ARTIFICIAL PANCREAS.** See also Bioartificial pancreas; Insulin infusion systems  
in insulin-dependent diabetes  
correlation between dietary carbohydrate and insulin delivery by, 101-105
- ASPARTIC ACID**  
and insulin aggregation, 83-85
- ASPIRIN**  
and blood platelet aggregation in diabetes, 488
- ATHEROSCLEROSIS**  
animal models of, \*60-61  
and arterial wall metabolism, \*5  
and comparison of two types of reaction to arterial wall injury, \*11-12  
in diabetes  
and blood viscosity elevation, \*102  
distribution of atherosclerotic plaques in, \*99  
and endothelium as barrier, \*100-101  
and fluid phase of coagulation, \*33-38  
and impaired glucose tolerance, \*58-59  
lipoproteins and, \*4-5  
physical factors in development of, \*97-103  
and endothelial injury, \*2-4, \*6, \*10-11  
effects of risk factors on, \*39-42  
and release from contact inhibition, \*21  
triglyceride-rich lipoproteins and, \*19-22  
environmental determinants, \*50  
and foam cells in atheroma, \*3  
herpesvirus-induced  
in chickens, \*29-31  
and high-density lipoprotein composition in insulin-dependent diabetes, 132, 136-137  
hyperglycemia as risk factor in, \*2, \*49-53  
and hyperinsulinemia, \*5  
and immunologic injury, \*9  
induced by intimal injury  
regression of, \*10  
and ischemic complications in diabetes, \*49-50  
lipoprotein metabolism in, \*60-65  
and mechanical injury to aortic wall, \*8-9  
antiplatelet serum prevention of, \*9
- mortality in diabetes and nondiabetics \*1  
noncoronary  
in diabetes, \*49-50  
and plasma lipoprotein abnormalities, \*82  
process of, \*1  
racial differences in incidence of, \*1  
and responses of arterial wall to endothelial injury, \*8-12  
role of arterial injury in pathogenesis of, \*18  
role of insulin  
in diabetes and nondiabetics, \*54-57  
shear stress model of, \*97-103, \*105  
and synergy of arterial injury and hypercholesterolemia, \*9  
types of lesions in humans, \*12  
wound-repair model of, \*39-42
- ATP.** See Adenosine triphosphate
- ATPase**  
sodium, potassium-, and effect of sucrose feeding on obese and normal mice, 975-978
- AUTOANTIBODIES**  
against insulin and somatomedin-C receptors, 979-981  
against insulin receptor  
molecular basis of interaction, 354-357
- AUTOGRAFTS**  
of islet cells in pancreatectomized dogs, 456-458
- AUTOIMMUNE DISEASE**  
and diabetes and lymphocytic thyroiditis in rats, 1058-1060
- AUTORADIOGRAPHY**  
of human mononuclear leukocytes, 128, 130
- 13-AZAPROSTANOIC ACID**  
and arachidonic acid-induced platelet aggregation in diabetes and nondiabetics, \*46-47

## B

### BASEMENT MEMBRANE

- dermal capillary, in insulin-dependent diabetes  
albumin deposition in, 275-278  
kidney  
albumin concentrations in diabetes, 843-845  
rat glomerular

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- nonenzymatic glycosylation of, 367-370
- thickening  
in skeletal muscle capillaries of diabetics, 326-333
- BICARBONATE**  
balance  
during recovery phase of diabetic ketoacidosis, 310-313
- BIOARTIFICIAL PANCREAS**  
in streptozotocin-diabetic rats, 296-301
- BIOSTATOR**  
in insulin action evaluation studies in diabetics, 650-655
- BLOOD**  
coagulation  
intrinsic and extrinsic pathway for, \*34-35  
coagulation, fluid phase  
and atherosclerosis of diabetes, \*33-38  
donor-specific pretreatment  
and pancreatic islet allograft survival in rats, 947-950  
erythrocytes  
insulin receptors in sheep, maturation and, 411-414  
measurement of irreversibly glycosylated hemoglobin in, 607-612  
erythrocytes metabolism  
during diabetic ketoacidosis and recovery phase, 346-352  
erythrocytes and monocytes  
insulin binding in normal and disease states, 896-901  
flow  
endothelial responses to, atherogenesis and, \*99-100  
hemoglobin A<sub>1</sub> assays  
chemical means for removing labile glycohemoglobin in, 700-701  
hydrogen ion concentration  
in metabolic acidosis, 781-782  
monocytes  
insulin binding studies, 196-201  
mononuclear leukocytes in humans with somatostatin and glucagon receptors, 127-131  
pH and diabetic ketoacidosis treatment, 311  
platelets, *see* Blood platelets  
samples  
in clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460  
in continuous central venous insulin infusion study, 711  
in gastric somatostatin study in streptozotocin-diabetic rats, 188  
in glucose utilization and exercise and insulin study, 984  
in glycogenolysis and gluconeogenesis study in conscious dog, 181  
in immunoglobulin G stimulation of adipocyte lipogenesis study, 1068-1069  
ultrafiltrate  
rat islets perfused with, in bioartificial pancreas, 296-301  
viscosity elevation in diabetic atherogenesis and, \*102
- BLOOD-BRAIN BARRIER**  
insulin receptor  
insulin binding to, 757-761
- BLOOD GLUCOSE**  
control  
and fibrinogen survival, \*36  
and nerve function, 459  
and platelet survival in diabetics, 486-489  
and pubertal stage, effects on somatomedin C in insulin-dependent diabetic children, 868-871  
in diabetic and normal mice, 108  
and evaluation of insulin action in diabetics, 650-655  
and exercise in normals and diabetics, 985  
and hyperglycemia in genetically diabetic mice, 91  
and insulin infusion pump in pregnant diabetics, 891-895  
and islet cell transplantation in streptozotocin-diabetic rats, 481  
levels  
and measurement of irreversibly glycosylated hemoglobin in unstable diabetes, 607-612  
measurement  
and hyperglycemia as risk factor for atherosclerosis, \*90-93  
and mixed meals and dextrose intake in insulin-dependent diabetics  
insulin delivery by artificial pancreas and, 101-105  
and renal hypertrophy in diabetic animals, 485  
response to carbohydrate  
acarbose and, 951-954
- BLOOD PLATELETS**  
activation in diabetics, \*42  
aggregation  
in cerebral and mesenteric microcirculation of mice with genetically determined diabetes, 89-92  
in insulin-dependent diabetics, \*45  
and prostacyclin production in diabetics, 935  
aggregation and ATP release  
after incubation with soluble immune complexes purified from diabetic serum, 575-578  
aggregation and coagulation  
and pathogenesis of retinopathy in streptozotocin-diabetic rats, 601-606  
and antiplatelet agents and fibrinogen survival, \*37  
antiserum to, and blocking of atherosclerosis, \*3  
arachidonic acid metabolism  
in diabetics, \*44-47  
and atherogenesis, \*3  
-derived growth factor  
atherogenesis and, \*9-10  
in diabetics, atherogenesis and, \*3-4  
\*42  
effects of atherosclerosis risk factors on, \*39-42  
factor 4  
in plasma of coronary artery disease, peripheral artery disease, and diabetic patients, \*33-34  
factors  
and intimal hyperplasia, \*9-10  
and fluid phase of coagulation in diabetic atherosclerosis, \*33-38  
function and turnover  
in hypercholesterolemia and diabetes, \*39  
hyperaggregation in diabetics, factors associated with, 488  
nonadhesion to endothelial cells from large and small vessels, \*26  
survival  
in diabetics, 486-489  
synthesis of prostaglandin endoperoxides  
and vascular disease, \*47
- BLOOD PRESSURE**  
systolic  
and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 630, 631, 632
- BLOOD SUGAR**  
of cold-adapted and control eels, 317-325  
and diabetes gene expression in mice, 1031  
effect on intestinal sugar transport  
structural specificity of, 571-572  
and exercise and insulin therapy, 983-988
- BLOOD VESSELS**  
cerebral and mesenteric  
platelet aggregation studies in genetically diabetic mice, 89-92  
large and small  
comparison of endothelial cells of, \*24-27

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



retinal  
microthrombus formation in streptozotocin-diabetic rats, 601-606  
transplantation of isolated islets via portal vein into diabetic mice, 285-290

# BODY

leg glucose uptake  
insulin and, 1000-1006

# BODY MASS INDEX

of insulin-resistant non-insulin-dependent diabetics, 991  
in rural-urban diabetes prevalence study in Polynesians, 49

# BODY WEIGHT

at birth  
of infants of diabetic mothers with insulin infusion pumps during pregnancy, 895  
in diabetic and normal mice, 107  
effect of streptozotocin in rats on, 189  
and expression of mutations at diabetes locus in mice, 1031  
and gastrointestinal insulinotropic hormones response to oral glucose in normal and gestational-diabetic pregnancy, 504-508  
and glycosuria in mice, 90  
in insulin and exercise and glucose utilization study, 983  
loss  
rat aorta 6-oxo-prostaglandin  $F_{1\alpha}$  production and, 937, 938  
and skeletal muscle morphology and enzyme activities, 19-25

# BONES

congenital lumbar and sacral malformations in offspring of diabetic rats and diabetic control during organogenesis, 965-969  
proteoglycans biosynthesis  
in streptozotocin-diabetic rats, 670-677

# BORDETTELLA PERTUSSIS

islet-activating protein purified from effect on immunoreactive insulin and glucagon secretion in normal, alloxan-treated, and depancreatized dogs, 430-434

# BOROHYDRIDE REDUCTION

of proteoglycans from diabetic rat bone and cartilage, 673

# BRAIN

cerebral cortex of diabetic rat  
extravasation of plasma proteins into, 500-503

cerebral edema  
following saline and insulin therapy in streptozotocin-diabetic rats, 762-766  
insulin binding to isolated microvessels, 757-761

# C

## CALCIUM

deficiency in diabetic rats, 383-384  
-dependent phosphatidylinositol breakdown and amylase secretion in rat pancreas  
insulin and insulin secretagogues and, 396-401  
and glucose-stimulated insulin release and trifluoperazine, 960-966  
in rat pancreatic islets  
glucose and, 52-54  
and somatostatin mechanism of action in pancreatic islet  $\beta$ -cells, 836-841  
and veratridine effects on glucagon and insulin secretion, 446-449  
and vitamin D  
and insulin secretion, 384-385  
and zinc-induced inhibition of insulin secretion from rat islets of Langerhans, 342, 343-344

## CALMODULIN

and glucose-stimulated insulin release and trifluoperazine, 960-966

## CALORIMETRY, INDIRECT

in exercise and insulin and glucose utilization study, 984, 987  
and insulin clamp studies, 1002

## CAPILLARIES

basement membrane width  
in parents of children with type I diabetes, 475-479  
from bovine cerebral cortex  
insulin binding to, 757-761  
of cold-adapted eels, 317-325  
density  
body weight and, 19, 20-21  
dermal basement membrane  
albumin deposition in insulin-dependent diabetics, 275-278  
skeletal muscle  
in diabetics, pericyte degeneration and basement membrane thickening in, 326-333

## CARBOHYDRATE

absorption  
and acarbose, 951-954  
dietary  
and degree of sialylation of apoC-III, 530-533

dietary, nature and amount  
correlation with insulin delivery by artificial pancreas in insulin-dependent diabetics, 101-105  
homeostasis  
zinc and, 341  
ingestion  
and postprandial hypoglycemia diagnosis, 996-999  
intolerance, in type II, non-insulin-dependent diabetics  
and measurement of in vivo insulin resistance, 618  
metabolism  
and gastric somatostatin, 188  
tolerance tests  
and acarbose effects on carbohydrate absorption, 951-954

## CARBON DIOXIDE

concentrations in expired air  
in glucose utilization and exercise study, 984  
serum levels  
increase during recovery phase of diabetic ketoacidosis, 310-313

## <sup>14</sup>CARBON DIOXIDE

conversion of <sup>14</sup>C-glucose into  
by perfused skeletal muscle of genetically obese-diabetic mice, 211-217

## CARDIOVASCULAR DISEASE. See also

Atherosclerosis  
atherosclerotic  
and high-density lipoprotein composition in insulin-dependent diabetics, 132-137  
plasma cholesterol as risk factor in, \*76, \*78

## CARDIOVASCULAR SYSTEM

and hyperglycemia, 222, 224-225

## CARTILAGE

proteoglycans biosynthesis  
in streptozotocin-diabetic rats, 670-677

## CASE REPORT

long-term continuous intraperitoneal insulin infusion system, 1072-1074

## CATECHOLAMINES

in diabetics with autonomic neuropathy, 626, 632  
microvessel response to  
in streptozotocin-diabetic Syrian hamsters, 94-100

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-962  
Supplement 2, 1-110  
December, 983-1113

**CAUCASIANS**

diabetic and nondiabetic  
urinary excretion and renal clearance  
of specific plasma proteins,  
compared with Pima Indians,  
656-662

**CELLS**

cultured rat islet tumor  
hormones and factors stimulating  
growth of, 1022-1027  
endothelial, *see* Endothelial cells  
fibroblasts from maturity-onset diabetics  
and unaffected relatives  
insulin binding and action in, 940-  
945  
Friend erythroleukemia  
alteration of fatty acid composition of,  
effects on insulin receptors of,  
773-779  
glucagon immunoreactive  
of two populations of ratfisch islet  
cells, 192-195  
human-mouse hybrids  
and location of human insulin gene  
from DNA isolated from, 267-  
270  
mouse lymphocyte hybrid  
and production of monoclonal anti-  
bodies reacting with rat islet  
cell membrane antigens, 226-  
230  
peritoneal exudate  
and rejection of islet allografts, 242-  
246  
rabbit aorta myomedial  
as model for diabetic macroangio-  
pathy, \*14-16  
rat spleen  
and rejection of islet allograft, 289-  
290  
smooth muscle  
and atherogenesis, \*9-10  
function in low oxygen environment,  
\*41  
insulin effects on, \*55-56  
insulin effects on lipid metabolism of,  
\*56-57  
proliferation, and atherogenesis  
pathogenesis, \*18  
proliferation in artery intima, \*39  
transport  
and microtubules, 539

**CESIUM CHLORIDE DENSITY GRADI-  
ENT CENTRIFUGATION**

in proteoglycans biosynthesis study in  
diabetic rats, 673, 674, 675

**CHICKENS**

herpesvirus-induced atherosclerosis in,  
\*28-31  
insulin-induced aortic lesions in, \*55

**CHILDREN.** *See also* Juvenile diabetes  
insulin-dependent diabetic  
effect of pubertal stage and blood  
glucose control on plasma so-  
matomedin C in, 868-871  
obese, of obese parents, hyperinsulin-  
ism studies in, 14-18

**CHINESE HAMSTERS**

diabetic  
dicarboxylic amino acids and preven-  
tion of insulin aggregation in,  
83-85  
diabetic and normal  
glycosaminoglycan from kidneys of,  
393-395

**CHLOROQUINE**

in <sup>125</sup>I insulin binding studies, 598  
and renal insulin uptake, 930-933

**CHLORPROPAMIDE ALCOHOL FLUSH**

plasma acetaldehyde increase as indi-  
cator of, 788-790

**CHOLESTEROL**

dietary  
and lipoprotein metabolism in ath-  
erosclerosis, \*60-65  
ester and free  
in injury-induced lesions in rabbit  
aorta, \*8-9  
in high-density lipoprotein particles  
diabetes and, \*5  
in insulin-dependent diabetics, 132-  
137  
levels  
and herpesvirus-induced athero-  
sclerosis in chickens, \*29-31  
metabolism  
in endothelial cells, \*20  
metabolism in diabetics  
diet and, \*76-81  
synthesis  
endothelial cell, \*22  
total  
in plasma of obese children of obese  
parents, 15-17

**CHROMATOGRAPHY**

affinity  
and radioimmunoassay of somatosta-  
tin-like immunoreactivity in  
human peripheral plasma, 471-  
474  
column  
and glycosylated hemoglobin assays,  
115  
DEAE-cellulose  
and collagen assays in arterial wall,  
\*16  
and protein activator of phosphodies-  
terase assays, 373-375

gas

and breath hydrogen levels, in acar-  
bose and carbohydrate absorp-  
tion study, 952, 953-954  
gel filtration  
of immunoreactive insulin released  
from adenoma tissues of nicotin-  
amide and streptozotocin-  
treated rats, 305, 306  
of somatostatin-like activity, 472  
and hepatic extraction of plasma im-  
munoreactive glucagon compo-  
nents in dogs, 768-771  
liquid  
and removal of labile glycohemoglo-  
bin in hemoglobin A<sub>1</sub> assay,  
700-701  
and measurement of glycosylated he-  
moglobin, 614  
molecular sieve  
of proteoglycans from diabetic rats,  
675-676  
sepharose  
in proteoglycans biosynthesis study,  
673

**<sup>51</sup>CHROMIUM**

-labeled platelets  
in platelet survival study in diabetics,  
486-489

**CHROMOSOMES**

location of human insulin gene on, 267-  
270

**$\alpha$ -CHYMOTRYPSIN**

and proteolysis in peripheral nerve  
myelin in streptozotocin-diabetic  
and normal rats, 292-294

**CHYMOTRYPTIC CLEAVAGE**

of <sup>125</sup>I-insulin, 2

**CIGARETTE SMOKING.** *See* Smoking

**COLCHICINE**

and insulin secretion in man, 1008-1012

**COLLAGEN**

and arterial stiffening in diabetes, \*101  
in arterial wall  
growth hormone and increase in, \*16  
of glomerular basement membrane from  
diabetic rats  
ketamine-linked glucose levels in,  
616

**COLLAGENASE**

and isolation of tumors from pancreas of  
nicotinamide and streptozotocin-  
treated rats, 302, 303  
perfusion of dog pancreatic duct with  
and preparation of viable islet cells,  
455-458

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# COLORIMETRY

and measurement of glycosylated hemoglobin, 614-615

# COMA, HYPOGLYCEMIC

and mortality, 177

# COMPLEMENT

C<sub>3</sub>, extravasation into cerebral cortex of diabetic rats, 500-503  
-fixing islet cell antibodies in serum from diabetic patients and insulin released from mouse islets incubated with, 1051-1056  
and islet-cell specific antibodies and insulin release from rat pancreatic  $\beta$ -cells, 231-234

# CONCAVALIN A

and glucose uptake by cultured human fibroblasts, 523-528

# CONGENITAL MALFORMATIONS

lumbosacral defects in neonatal rat offspring and diabetic control during organogenesis, 955-959

# COSYNTROPIN

infusion in hyperkalemic and normokalemic diabetics  
plasma cortisol and aldosterone and, 337-339

# COWS

inhibition of superoxide dismutase by diabetogenic drugs, 235-240

# COXSACKIE VIRUS B4

and HLA antigens in juvenile diabetics and siblings in prospective study, 584-589

# CREATININE

clearance  
and aldose reductase inhibition in diabetic neuropathy, 460

# CYCLOC AMP

and glucose-induced insulin secretion in fetal and neonatal rat pancreas, 60, 62  
in isolated rat islets  
prostacyclin and 6-keto-prostaglandin F<sub>1 $\alpha$</sub>  and, 824-827  
liver production of  
and glucagon stimulation, 185  
phosphodiesterase and protein activator of  
in adipose tissue from insulin-treated streptozotocin-diabetic rats, 372-375  
and somatostatin and insulin secretion from isolated, perfused rat pancreas, 40-44

# CYCLOHEXIMIDE

-inhibition of protein synthesis and intestinal sugar transport in rats, 572

# CYTOTOXICITY STUDIES

of lymphocyte tissue, 227

## D

# 2 DEOXY-D-GLUCOSE

-induced hyperglycemia  
and wound healing in mice, 407-410  
uptake by cultured human fibroblasts insulin and insulin-like agents and, 523-528

# DEXTROSE

ingestion  
and insulin delivery by artificial pancreas in insulin-dependent diabetics, 101-105

# DIABETES MELLITUS

and albumin concentrations in kidney basement membranes, 843-845  
arterial stiffening in, \*101  
and atherogenesis, \*3-4  
and atherosclerosis  
and fluid phase of coagulation, \*33-38  
mortality, \*1  
and "non-coronary cardiopathy," \*49-50  
physical factors in development of, \*97-103  
blood clotting assays in, \*35  
and blood platelet survival, 486-489  
causes of endothelial injury in, \*2  
in Chinese hamsters  
and amino acids effects on insulin aggregation, 83-85  
and kidney glycosaminoglycan, 393-395  
and cholesterol metabolism  
diet and, \*76-81  
classifications  
and insulin resistance in type II diabetes, 739-744  
and clotting factor levels, \*35-36  
and complement-fixing islet cell antibodies  
incubation of isolated mouse islets with sera from, 1051-1056  
control  
and high-density lipoprotein and cholesterol levels, \*89  
and long-term continuous intraperitoneal insulin infusion system, 1073-1074  
and measurement of irreversibly glycosylated hemoglobin, 607-612

and decreased bone formation  
and cartilage and bone proteoglycans biosynthesis abnormalities in diabetic rats, 670-677  
diet-treated, maturity onset  
and brief, irregular oscillations of basal plasma insulin and glucose concentrations, 435-439  
duration  
arterial calcification and, \*14  
urinary excretion and renal clearance of specific plasma proteins and, 656-662  
and elevated blood viscosity  
atherogenesis and, \*102  
encephalomyocarditis virus-induced in mice  
genetic obesity and, 451-454  
endothelial cell studies in, \*41-42  
and endothelial injury, \*2-3  
and evaluation of insulin action of highly purified beef and pork insulins and conventional insulins, 650-655  
and exercise  
and glucose utilization, insulin and, 983-988  
glycosylated hemoglobin structure and synthesis in, 613-616  
and heredity  
and identification of insulin gene, 270  
high-density lipoproteins in, \*82-85  
and hyperkalemia  
and renin-angiotensin-aldosterone system, 335-339  
and hypertriglyceridemia  
and atherosclerosis, \*4-5  
and impaired wound healing, 407  
and inhibitors of coagulation proteases, \*36  
insulin-dependent  
and albumin deposition in dermal capillary basement membrane, 275-278  
continuous subcutaneous insulin infusion and correction of exercise-induced microalbuminuria in, 818-822  
and correlation between dietary carbohydrate and insulin delivery by artificial pancreas in, 101-105  
epidemiologic characteristics of, and prospective study of viral antibody titers and HLA-B locus antigens, 584-589  
and erythrocyte and monocyte insulin binding studies, 896-901  
high-density lipoprotein composition in, 132-137  
and high-density lipoprotein metabolism, \*84-85  
incidence in Allegheny County, Pennsylvania, 279-283

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# SUBJECT INDEX 1981

- with microvascular disease, acetylator phenotypes in, 907-909
  - nucleic acid antibodies in, 873-874
  - spontaneous in rats, and lymphocytic thyroiditis, 1058-1060
  - insulin-dependent, adult-onset pneumococcal immunization in, 119-121
  - and insulin metabolism
    - and atherosclerosis, \*55
  - insulin- and non-insulin-dependent and hypertriglyceridemia, \*66, \*67, \*68-69, \*70, \*71-74
  - insulin-resistant
    - and simultaneous inhibition of insulin and somatomedin-C binding to cultured IM-9 lymphocytes from, 979-981
  - insulin treated
    - and polymorphonuclear leukocytes-stimulated glucose oxidation and iodination, 256-259
  - juvenile-onset
    - long-term study of mortality and vascular complications in, 175-178
    - lymphocytotoxic antibodies and histocompatibility antigens in, 26-29
    - with and without autonomic neuropathy, and hormonal, metabolic, and cardiovascular responses to insulin-induced hypoglycemia, 626-632
  - maternal
    - and immunocytochemical study of pancreatic specimens from infants of, 271-273
  - maturity-onset of the young
    - insulin binding and action in fibroblasts from, 940-945
  - in mice
    - and influence of H-2 haplotype and sex on expression of, 1029-1034
    - and prevention of nephropathy by diet control, 106-111
  - and microangiopathy, 93-94, 100
  - mild
    - and epinephrine-propranolol infusions for measurement of insulin resistance, cardiac arrhythmias during, 618-620
  - mild and severe
    - and plasma glucose, insulin, and C-peptide response to glucagon injection, 685-692
  - in new strain of genetically obese-hyperglycemic rat, 1045-1049
  - non-insulin-dependent
    - and chlorpropamide alcohol flush, plasma acetaldehyde as indicator of, 788-790
    - effects of insulin therapy on insulin resistance in, 739-744
    - and glucose utilization during glucose clamp studies, 829-834
  - and hyperinsulinemia, \*1-2
  - and hyperinsulinemia and atherogenesis, \*5
  - and hypertriglyceridemia, \*70
  - insulin binding, internalization, and insulin receptor regulation in fibroblasts from, 596-600
  - insulin resistance in, 157-160, 990-995
  - and insulin resistance study in fibroblasts, 562-566
  - islet secretion in new animal model of, 590-594
  - and mortality from atherosclerosis, \*1
  - and obesity in mice
    - and hormone regulation of glucose metabolism, 211-217
  - and pathophysiology of metabolic acidosis, 781-786
  - platelet arachidonic acid metabolism in, \*44-47
  - prevalence
    - in rural and urban Polynesian population of Western Samoa, 45-50
  - and renal impairment
    - and defective hydroxylation of phenformin, 644-649
  - serum glycosidase activity in, 115-117
  - skeletal muscle capillaries and, 326-333
  - soluble immune complexes from serum
    - platelet aggregation and ATP release after incubation with, 575-578
  - and symptomatic polyneuropathy
    - comparison of clinical course and sequential electrophysiological test results and myo-inositol therapy, 139-147
  - Vacor-induced, 235
  - and Wistar "BB" rats
    - and T-cell lymphocytopenia, 887-889
- DIET**
- and cholesterol metabolism in diabetes, \*76-81
  - comparison of oral glucose tolerance tests and mixed meals in hypoglycemic patients, 465-469
  - composition
    - in triphenyltin fluoride and hypertriglyceridemia study in rabbits, 1014
  - fiber supplements
    - and carbohydrate absorption, 951
  - high-carbohydrate
    - in starved alloxan diabetic rats, and hepatic 2,6-bisphosphate levels, 1062-1064
  - high-fat-high cholesterol
    - and lipoprotein metabolism in atherosclerosis, \*60-65
  - intake
    - of triphenyltin fluoride-treated rabbits, 1015
  - and juvenile-onset diabetes, 176
  - mixed meals and dextrose intake
    - and insulin delivery by artificial pancreas in insulin-dependent diabetics, 101-105
  - and plasma lipids and cholesterol, \*88
  - and plasma removal of very-low-density lipoproteins in insulin-deficient rats, 496-497, 498
  - and prevention of diabetic nephropathy in diabetic mice, 106-111
  - sucrose overfeeding
    - and Na, K-ATPase-mediated potassium uptake in normal and obese mice, 975-978
- DIHYDROXYACETONE**
- and somatostatin release from pancreatic D-cells, 205-207
- I,25 DIHYDROXYVITAMIN D<sub>3</sub>**
- and insulin secretion, 382-385
- DNA.** See also Recombinant DNA methodology
- antibodies to
    - in insulin-dependent diabetics and unaffected relatives, 873-874
  - of cultured rat pancreatic islets
    - myo-inositol inhibition of <sup>3</sup>H-thymidine incorporation into, 622, 623-624
  - in fetal and neonatal rat islet of Langerhans
    - insulin secretion and, 58-59
  - kidney cell content
    - in streptozotocin-diabetic rats, 484, 485
  - and location of human insulin gene, 267-270
  - synthesis
    - in cultured monkey aortic smooth muscle cells, insulin effects on, \*55-56
- DOGS**
- alloxan diabetic
    - hypersomatostatinemia of insulin deficiency and high plasma free fatty acid levels in, 358-360
  - effect of digested and undigested gluten on postprandial insulin and glucagon levels in, 362-364
  - glucagon and glycogenolysis and gluconeogenesis study in, 180-186
  - hepatic extraction of plasma immunoreactive glucagon components in, 767-779
  - and hypophosphatemia
    - and insulin responses, 384
  - inhibition of erythrocyte superoxide dismutase by diabetogenic drugs in, 235-240
  - liver glucose production in
    - glucagon deficiency and, 490-494

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- liver secretion of  $\beta$ -very-low-density lipoproteins in, \*63-64
- normal
- oxytocin infusion and plasma insulin and glucagon levels and glucagon production and uptake in, 112-114
- normal, alloxan-treated, and depancreatized
- effect of islet-activating protein on immunoreactive insulin and glucagon secretion in, 430-434
- normal and vagotomized
- effect of somatostatin on thoracic duct lymph flow rate and triglyceride levels in, 440-444
- pancreas
- D-cell recognition of D-glucose, 203-209
  - preparation of viable islet cells from, 455-458
  - protein- and acid-induced splanchnic somatostatin release in insulin and, 735-738
  - somatostatin-suppression of portal and peripheral insulin concentrations in
  - glucose and changes in, 664-668

# **DOPAMINE- $\beta$ -HYDROXYLASE**

- increased activity in streptozotocin-diabetic rats
- characterization of, 416-423

# **DROSOPHILA MELANOGASTER**

- insulin content, 70-75

## **E**

**EARTHWORMS.** See Annelids

# **EDEMA**

- cerebral
- and extravascular escape of albumin into cerebral cortex of diabetic rats, 500-503
- following fluid and insulin therapy in streptozotocin-diabetic rats, regional localization of, 762-766

# **EELS**

- cold-adapted
- hyperglycemia and microangiopathy in, 317-325

# **ELECTRICAL ACTIVITY**

- of pancreatic islet cell membrane
- effects of glucose and acetylcholine on, 558-561

# **ELECTROCARDIOGRAMS**

- abnormalities
- and glucose intolerance and arterial disease, \*50-52

# **ELECTROLYTES**

- serum and urinary
- during recovery phase of diabetic ketoacidosis, 310-313

# **ELECTROPHORESIS**

- and analysis of glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393-395
- and measurement of glycosylated hemoglobin, 614, 615
- polyacrylamide gel
- of  $^{125}$ I-insulin, 2, 3
- and superoxide dismutase assays, 236, 239-240
- and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701
- sodium dodecyl sulfate-polyacrylamide gel
- in autoantibodies against insulin receptor study, 354-357
- and collagen assays in arterial wall, \*16

# **ELECTROPHYSIOLOGICAL STUDIES**

- of diabetics with symptomatic polyneuropathy
- compared with clinical course, 139-147
- of somatostatin mechanism of action in pancreatic islet  $\beta$ -cells, 836-841

# **ENCEPHALOMYOCARDITIS VIRUS**

- induced diabetes in mice
- effects of genetic obesity on, 451-454

# **ENDOCRINE GLANDS**

- and lymphocytic thyroiditis in diabetic insulin-treated rats, 1058-1060

# **ENDOTHELIAL CELLS**

- as barrier
- atherogenesis in diabetics and, \*100-101
- cholesterol metabolism, \*20
- contact inhibition in culture, \*20
- function in low oxygen environment, \*41
- homocystinuria as model of platelet response to injury to, \*40
- injury
- and risk factors for atherosclerosis, \*39-42
- in large and small vessels, \*32
- comparison of, \*24-27
- features common to, \*25-26

- migration of, \*26-27
- nutritional requirements, \*26
- substratum requirements for growth of, \*26
- migration
- and wound-repair response, \*40
- receptors for triglyceride-rich lipoproteins, \*19-22

**ENDOTHELIUM.** See also Endothelial cells permeability and wall shear stresses atherogenesis and, \*101 responses to blood flow atherogenesis and, \*99-100

# **ENVIRONMENTAL FACTORS**

- and atherosclerosis in diabetics, \*50, \*58

# **ENZYMES**

- angiotensin-converting
- in endothelial cells of large and small vessels, \*25
- electrophoretic analysis of
- location of insulin gene and, 267
- glycogen synthase and pyruvate dehydrogenase activities
- in skeletal muscle of genetically obese-diabetic mice, 216
- glycolytic
- and glucose metabolism in rat pancreatic islets, 923-928
- iodotyrosine
- metabolism in diabetic rats, 694-698
- ornithine decarboxylase
- regulation in skeletal muscle from diabetic fed and starved rats, 675-683
- in pancreatic islets
- glucose metabolism regulation and, 911-921
- 6-phosphofructo 1-kinase activation
- assay for fructose 2,6-bisphosphate
- in alloxan diabetic rat liver, 1062-1064
- serum glycosidic
- in diabetics and normals, 115-117
- skeletal muscle
- and fasting serum insulin and glucose tolerance, 19-25
- superoxide dismutase
- inhibition by diabetogenic drugs, 235-240
- transmitter
- retrograde axonal transport in streptozotocin-diabetic rats, 797-802
- trypsin and  $\alpha$ -chymotrypsin
- and proteolysis in peripheral nerve myelin in streptozotocin diabetic and normal rats, 292-294

## **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



# **EPIDEMIOLOGICAL STUDIES**

of role of abnormal insulin response to oral glucose and atherosclerosis in diabetics and nondiabetics, \*54-55

# **EPINEPHRINE**

effects on phosphorylase activity and glucose metabolism by skeletal muscle of genetically obese-diabetic mice, 214-215  
propranolol, glucose, and insulin infusions for measurement of insulin resistance in mildly diabetic or hyperlipidemic men  
cardiac arrhythmias during, 618-620 and recovery from hypoglycemia, 262-263

# **EPITHELIAL CELLS.** See also Epithelium

blockade of lipoprotein interiorization, \*20-21  
from large and small vessels  
formation of three-dimensional networks in vitro, \*27

# **EPITHELIUM**

ciliary and retinal pigmented and glucose transport across ocular barriers of diabetic rats, 903, 905

# **ERYTHROCYTES**

incubation in semicarbazide and aniline and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701  
insulin binding  
in normal and disease states, 896-901  
insulin receptors  
disappearance during maturation in sheep, 411-414  
metabolism  
during diabetic ketoacidosis, 346-352  
oxygen transport in diabetics and arterial injury from hypoxia, \*2

# **17 $\beta$ -ESTRADIOL**

and expression of mutations at diabetic locus in male mice, 1036, 1037-1038

# **ESTRADIOL BENZOATE**

and skeletal muscle metabolism in rats, 548-550

# **ETHANOL**

effects on insulin and glucagon secretion  
in perfused rat pancreas, 705-708

# **EUGLYCEMIC GLUCOSE CLAMP TECHNIQUE**

assessment of insulin resistance with insulin suppression test and, 387-392  
and evaluation of insulin action in diabetics, 650-655  
and glucose utilization and clearance study in normal man, 535-537  
and insulin and glucose effects on sympathetic nervous system activity in normal man, 219-225  
and insulin and intravenous glucose disposal study, 1000-1006  
and insulin resistance studies, 151-155  
prolonged  
enhanced glucose utilization during, 829-834

# **EXERCISE**

and glucose utilization  
in normal and diabetic subjects, insulin and, 983-988  
-induced microalbuminuria  
in insulin-dependent diabetics, correction with continuous subcutaneous insulin infusion, 818-822  
and insulin-dependent diabetics  
blood glucose control and, 822

# **EXORPHINS**

and plasma insulin and glucagon levels in dogs, 362-364

# **EYES.** See also Retinopathy, diabetic

glucose transport across ocular barriers of, in streptozotocin-diabetic rats, 903-905

# **F**

# **FACTOR VIII**

in diabetics, \*35-36

# **FAMILY STUDIES**

of insulin binding and action in fibroblasts from patients with maturity-onset diabetes of the young and unaffected relatives, 940-945  
siblings of juvenile diabetics  
viral antibody titers and HLA B locus antigens in, 584-589

# **FASTING**

in alloxan diabetic rats  
and coagulation studies, \*36-37  
and glucose use and insulin release in rat pancreatic islets, 923-928

# **FATS**

dietary  
and lipoprotein metabolism in atherosclerosis, \*60-65

# **FATTY ACIDS**

composition of Friend erythroleukemia cells  
effect on insulin receptors of, 773-779  
free  
and exercise in diabetics and normals, 985  
high plasma levels, and hypersomatostatinemia of insulin deficiency, 358-360

# **FECAL BILE ACIDS**

and sterol balance techniques  
in cholesterol metabolism studies, \*78-81

# **FECAL NEUTRAL STEROIDS**

and sterol balance techniques  
in cholesterol metabolism studies, \*78-81

# **FEET**

and peripheral vascular disease in diabetics, \*49-50

# **FETUS**

human  
stomach glucagon content, 879-882 and maternal hyperglycemia, 271, 273  
mouse pancreas  
organ culture conditions and insulin and glucagon secretion, 804-811

rat  
glucose-induced insulin secretion in, 56-62

rat pancreas  
transplantation into adult diabetic rats, 9-12

# **FIBRINOGEN**

in diabetics, \*36  
turnover  
in coagulation studies, \*36-37

# **FIBRINOLYTIC SYSTEM**

in diabetes, \*36

# **FIBROBLASTS**

cultured human diploid  
effects of insulin and insulin-like agents on glucose transport system of, 523-528  
effect of pH and 3-hydroxybutyrate on insulin binding and action in, 402-405  
and glycosylated low density lipoproteins, 876-877

# DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

low-density lipoprotein receptors on, \*60  
and maturity-onset diabetes of the young  
insulin binding and action in, 940-945

# **FIBRONECTIN**

accumulation in arterial wall  
diabetic serum and growth hormone and, \*16  
and atherogenesis, \*5

# **FICOLL-HYPAQUE METHOD**

and identification of human somatostatin  
and glucagon receptor-bearing human mononuclear leukocytes, 127-131

# **FRIEND ERYTHROLEUKEMIA CELLS**

insulin receptors  
alteration of fatty acid composition on, 773-779

# **P-FRUCTOKINASE**

and regulation of glucose metabolism in rat pancreatic islets, 915, 916

# **FRUCTOSE**

and somatostatin, insulin, and glucagon release, 207-209

# **FRUCTOSE 2, 6-BISPHOSPHATE**

in rat liver  
and alloxan diabetes and starvation and refeeding, 1062-1064

# **FUCOSE**

-labeled protein  
rapid axonal transport in diabetic rats, 797-802

# **FUROSEMIDE**

and acetazolamide  
and renal insulin uptake, 930-933

## **G**

# **GALACTITOL**

accumulation in peripheral nerves and lens of diabetic rats, 459

# **GALACTOSE**

and somatostatin, insulin, and glucagon release, 207-209

# **$\beta$ -GALACTOSIDASE**

in diabetic and normal serum, 115-117

# **GAMMA-AMINOBUTYRIC ACID**

agonists, See Muscimol

# **GANGRENE**

and diabetes, \*49

# **GASTRIC EMPTYING**

in pregnancy  
and reduced gastric inhibitory polypeptide response to oral glucose, 508

# **GASTRIC INHIBITORY POLYPEPTIDE**

response to oral glucose  
in normal and gestational-diabetic pregnancy, 504-508

# **GASTROINTESTINAL SYSTEM**

and carbohydrate absorption  
acarbose and, 951-954  
D-cells  
hyperfunction in streptozotocin-diabetic rats, pancreas transplantation and, 724-726  
gastric somatostatin concentration and secretion  
in streptozotocin-diabetic rats, 188-191  
glucose uptake in diabetic rats, 247-255  
gut glucagon-like immunoreactivity transformation into pancreatic glucagon in piglets, 792-794  
and hyperinsulinemic response to oral glucose and atherosclerosis, \*54  
insulin absorption in rats  
and sodium 5-methoxysalicylate, 1065-1067  
insulinotropic hormones response to glucose  
in normal and gestational-diabetic pregnancy, 504-508  
intraoperative long-term continuous insulin-infusion system, 1070-1074  
protein- and acid-induced splanchnic somatostatin release in dogs  
insulin and, 735-738  
small intestine  
reductase activity in diabetic rats, and hypercholesterolemia, \*80-81  
sugar transport  
in streptozotocin-diabetic rats, 568-574  
total duodeno-pancreatectomy and gastrectomy in humans, glucagon immunoreactivity and somatostatin action in, 851-855  
triglyceride secretion  
in streptozotocin-diabetic rats, \*68

# **GEL FILTRATION**

Sephadex  
and human plasma somatostatin radioimmunoassay, 728-733

# **GENES**

HLA-DR4 antigens  
and capillary basement membrane width in parents in type I juvenile diabetics, 475-479  
mutant in mice  
expression of, H-2 haplotype and sex and, 1029-1034  
and secretion of structurally abnormal insulin molecule, 148  
transfer from Zucker rat to Wistar Kyoto rat  
new genetically obese-hyperglycemic rat bred from, 1045-1049

# **GENETICS. See also Genes; Heredity**

insulin gene location, 267-270  
and lymphocytotoxic antibodies and histocompatibility antigens in juvenile-onset diabetics, 26-29

# **GLUCAGON**

-binding mononuclear leukocytes in human blood, 127-131  
concentrations in diabetics with induced hypoglycemia  
autonomic neuropathy and, 628, 629, 631  
content of rat pancreas  
during postnatal development, 814-816  
deficiency  
and liver glucose production in dogs, 490-494  
and glycogenolysis and gluconeogenesis  
in conscious dog, 180-186  
immunoreactive  
effect of islet-activating protein on secretion of, in normal, alloxan-treated and depancreatized dogs, 430-434  
hepatic extraction of components of, 767-779  
immunoreactivity  
of ratfish islets, 192-195  
in totally duodeno-pancreatectomized and gastrectomized humans, 851-855  
-induced somatostatin release in perfused stomach of streptozotocin-diabetic rats  
pancreas transplantation and, 724-726  
and insulin levels in dogs  
exorphins and, 362-364  
oxytocin infusion and, 112-114  
and insulin requirements in postpancreatectomized patients, 641-642  
levels  
and exercise in diabetics and normals, 385

## **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

-like immunoreactivity, gut response to oral glucose  
in normal and gestational-diabetic pregnancy, 504-508  
-like immunoreactivity of pig gut transformation into pancreatic glucagon, 792-794  
in pancreatic specimens from infants of diabetic mothers, 271-273  
plasma glucose, insulin, and C-peptide response to injection of  
in normal and mildly and severely diabetic subjects, 685-692  
and recovery from hypoglycemia, 262-263  
responses to mixed meals  
in hypoglycemic patients and controls, 468, 469  
secretion  
from fetal mouse pancreas, effect of culture conditions on, 804-811  
in perfused rat pancreas, ethanol, acetaldehyde, and acetate and, 704-708  
veratridine and calcium and, 446-449  
and somatostatin suppression of insulin secretion in dogs  
portal and peripheral measurements and, 664-668  
-stimulated insulin release  
in triphenyltin fluoride-treated rabbits, 1016  
in stomach of human fetuses, 879-882

#### GLUCOKINASE

and adaptation of glycolytic enzymes in rat pancreas islets to starvation and refeeding, 924-928  
and regulation of glucose metabolism in rat pancreatic islets, 911-921

#### GLUCONEOGENESIS

and glycogenolysis in conscious dog  
differential time course of glucagon effect on, 180-186

#### GLUCOSE

and arachidonic acid- and epinephrine-induced platelet aggregation  
in insulin-dependent diabetics, \*45  
basal plasma  
brief, irregular oscillations of concentrations in diabetics, 435-439  
and calcium content of rat pancreatic islets, 52-54  
and calcium-dependent phosphatidylinositol breakdown and amylase secretion in rat pancreas, 396-401  
clearance  
and hyperglucagonemia in dogs, 185-186  
concentrations in isolated rat islets

and effects of prostacyclin and 6-keto-prostaglandin  $F_{1\alpha}$  on insulin secretion and cyclic AMP content, 824-827  
counterregulation in man, 261-263  
disposal  
measurement of, 847-850, 1000-1006  
and electrical activity in perfused, isolated mouse islets of Langerhans  
acetylcholine effects compared with, 558-561  
hepatic production in insulinoma patients  
insulin suppression of, 377-380  
high doses in neonatal rat model for non-insulin-dependent diabetes  
insulin, glucagon, and somatostatin responses to, 591-594  
homeostasis  
and idiopathic postabsorptive hypoglycemia, 465-469  
incorporation into cultured human fibroblasts, 403  
-induced hyperkalemia in diabetics and renin-angiotensin-aldosterone system, 335-339  
-induced insulin and glucagon secretion in perfused rat pancreas  
ethanol and acetaldehyde and acetate and, 705-708  
-induced insulin secretion  
in fetal and neonatal rat, 56-62  
and prostaglandin E synthesis in neonatal rat pancreas, 551-557  
and sites of action of trifluoperazine, 960-966  
in triphenyltin fluoride-treated rabbits, 1015-1016  
vincristine and, 539-544  
induced insulin release from rat pancreatic  $\beta$ -cells  
islet cell surface antibodies and complement and, 231-234  
zinc and, 341-344  
-induced insulin secretion in normal subjects  
correlation with urinary C-peptide excretion, 639-642  
infusions  
and evaluation of insulin action in diabetics, 650-655  
and insulin resistance and therapy in type II diabetics, 739-744  
and insulin infusions in normal man  
sympathetic nervous system activity and, 219-225  
and insulin and C-peptide response to glucagon injection  
in normals and mild and severe diabetics, 685-692  
insulin response to  
in familial obesity, 14-18  
intestinal uptake in diabetic rats, 247-255

intolerance  
and atherosclerosis, \*50-52, \*58-59  
liver production  
and glucagon deficiency in dogs, 490-494  
loading test  
and effect of islet-activating protein in dogs, 432  
metabolic clearance rate  
and relationship of glucose utilization rate to glucose concentration, 847-850  
metabolism  
in rat pancreatic islets, and adaptation of glycolytic enzymes to starvation and refeeding, 923-928  
regulation in pancreatic islets, islet glucokinase, hexokinase, glyceraldehyde-P dehydrogenase, and P-fructokinase and, 911-922  
net disposal  
and insulin dose-response kinetics, in insulin-resistant non-insulin-dependent diabetics, 992  
and nonenzymatic glycosylation of rat glomerular basement membranes, 367-370  
oral  
gastrointestinal insulinotropic hormones response to in normal and gestational-diabetic pregnancy, 504-508  
insulin responses to, and atherosclerosis in diabetics and nondiabetics, \*54-57  
oxidation and iodination stimulated by polymorphonuclear leukocytes from insulin-treated diabetics, 256-259  
plasma insulin response to  
and atherosclerotic vascular disease risk, \*58-59  
production and uptake in normal dogs  
oxytocin infusions and, 112-114  
renal clearance of  
in diabetic ketoacidosis, 510-517  
and somatostatin, insulin and glucagon release  
compared to fructose, galactose, and ribose, 207-209  
and somatostatin and insulin secretion from isolated, perfused rat pancreas, 40-44  
and somatostatin release  
and D-cell recognition of D-glucose, 203-209  
and somatostatin suppression of insulin secretion in dogs  
portal and peripheral measurements and, 664-668  
-stimulated somatostatin and insulin release from isolated perfused rat pancreas

#### DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

muscimol and, 168-170  
tolerance  
impaired, hypertriglyceridemia in diabetic humans and rats, and \*68-69  
transfer from blood to bioartificial pancreas, 297, 298  
transport  
across ocular barriers in streptozotocin-diabetic rat, 903-905  
by cultured human fibroblasts, effects of insulin and insulin-like agents on, 523-528  
uptake  
in different mouse skeletal muscles, 702-704  
uptake by erythrocytes  
in insulin receptor study in sheep, 412-414  
utilization  
and exercise in normal and diabetic subjects, insulin and, 983-988  
during prolonged glucose clamp studies, 829-834  
utilization and clearance in normal man  
effects of plasma glucose concentration on, 535-537

**GLUCOSE CLAMP TECHNIQUE.** See Euglycemic glucose clamp technique

**<sup>14</sup>C-GLUCOSE**  
and nonenzymatic glycosylation of rat glomerular basement membranes, 367-370

**GLUCOSE METABOLISM**  
in fibroblasts from diabetics and nondiabetics  
insulin and, 562-567  
in genetically obese-diabetic mice, 211-217

**GLUCOSE OXIDASE METHOD, 115**  
and plasma glucose levels in mice, 90

**GLUCOSE TOLERANCE**  
in insulin-resistant non-insulin-dependent diabetics, 990, 992  
in pregnancy, 504  
and skeletal muscle morphology and enzyme activities, 19-25  
and vincristine effects on glucose- and arginine-induced insulin release in rat pancreas, 539-544

**GLUCOSE TOLERANCE TESTS**  
and diagnosis of postprandial hypoglycemia, 996-999  
oral  
chemical hypoglycemia after, and absence of hypoglycemia after mixed meals, 465-469  
in hyperkalemic diabetics, 336, 337

in obese children of obese parents, 15-18  
in streptozotocin diabetic rats with fetal pancreatic grafts, 10, 11-12

**<sup>13</sup>C-GLUCOSE**  
and exercise and insulin, 983-988

**<sup>14</sup>C-L-GLUCOSE**  
transport across ocular barriers in streptozotocin-diabetic rats, 903-905

**D-GLUCOSE**  
pancreatic D-cell recognition of, 203-209

**$\beta$ -GLUCURONIDASE**  
in diabetic and normal serum, 115-117

**$\alpha$ -GLUCOSIDE HYDROLASE INHIBITORS**  
and carbohydrate absorption, 951-954

**GLUTAMIC ACID**  
and insulin aggregation, 83-85

**GLUTEN**  
digested and undigested  
and postprandial insulin and glucagon levels in dogs, 362-364

**GLYCERALDEHYDE**  
and somatostatin release from pancreatic D-cells, 205-207

**GLYCERALDEHYDE-P-DEHYDROGENASE**  
and regulation of glucose metabolism in rat pancreatic islets, 915, 916

**GLYCOGEN SYNTHASE**  
and effect of pH and 3-hydroxybutyrate on insulin binding and action in cultured human fibroblasts, 402-405  
in fibroblasts of diabetics and nondiabetics, 564, 566  
in skeletal muscle of genetically obese-diabetic mice  
insulin and, 216

**GLYCOGENOLYSIS**  
and gluconeogenesis in conscious dog  
differential time course of glucagon effect on, 180-186

**GLYCOHEMOGLOBIN**  
labile  
chemical means for removing in hemoglobin A<sub>1</sub> assay, 700-701

**GLYCOLYTIC INTERMEDIATES**  
in erythrocytes from diabetics with ketoacidosis  
insulin therapy and, 346-352

**GLYCOPROTEINS**  
retrograde axonal transport in diabetic rats, 797-802  
and serum glycosidase activity in diabetics and normals, 115

**GLYCOSAMINOLGLYCAN**  
from kidneys of diabetic and normal Chinese hamsters, 393-395

**GLYCOSIDIC ENZYMES**  
in serum of diabetics and normals, 115-117

**GLYCOSYLATION**  
nonenzymatic  
of low-density lipoproteins, 875-877  
of rat glomerular basement membranes  
nonenzymatic, 367-370

**GONADEXOTOMY**  
and expression of mutations at diabetic locus in male mice, 1036-1037, 1038

**GROWTH**  
in diabetic and normal mice, 107  
of fetal rat pancreas transplanted into streptozotocin-diabetic rats, 11-12  
of RIN-r rat islet tumor cells in serum free medium  
hormones and factors stimulating, 1022-1027

**GROWTH HORMONE**  
and diabetic macroangiopathy, \*14-15, 16  
and rabbit arterial myomedial cell growth, \*14-16  
and rat islet tumor growth in serum-free medium, 1022-1027  
responses  
in hypoglycemic diabetics with and without autonomic neuropathy, 628, 631  
and somatostatin action, 851-855

## H

**HAMSTERS.** See Golden hamsters; Syrian hamsters

**H-2 HAPLOTYPE**  
and expression of mutations at diabetes locus in mice, 1029-1034

**HASHIMOTO'S THYROIDITIS**  
and diabetes in man, 1059-1060

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# HEART

cardiac arrhythmias during epinephrine-propranolol infusions for measurement of insulin resistance, 618-620

rat aorta

6-oxo-prostaglandin  $F_{1\alpha}$  production, diabetes, insulin, and caloric deprivation and, 935-938

rate

and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 630, 631, 632

# HEART DISEASE

coronary

hypertension as risk factor in insulin-dependent juvenile onset diabetes for, \*90-96

in diabetes

and diabetic macroangiopathy and growth hormone, \*14-16

and diabetic microangiopathy and macroangiopathy, \*14

ischemic

and abnormal insulin response to glucose, \*54, \*55

in diabetics, \*49-50

and lipoproteins, \*4-5

# HEMOGLOBIN

glycosylated

in clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460, 461-462, 463

in diabetics and normals, 115

and insulin infusion pump in pregnant diabetics, 892-893

structure and synthesis in diabetics, 613-616

methods of measurement of, 614-615

irreversibly glycosylated

importance of estimation in diabetics, 607-612

# HEMOGLOBIN A<sub>1</sub>

assays

and removal of labile glycohemoglobin, 700-701

# HEMOGLOBIN A<sub>1c</sub>

and hypoxic arterial damage, \*2

# HEPARIN

and fibrinogen survival in hyperglycemic diabetics, \*37

# HEREDITY

acetylator phenotypes

in insulin-dependent diabetics with microvascular disease, 907-909

and expression of mutations at diabetes locus in mice

H-2 haplotype and sex and, 1029-1034, 1035-1043

nucleic acid antibodies in insulin-dependent diabetics and unaffected relatives, 873-874

# HEXOKINASE

in gastrocnemius muscle tissue

fasting serum insulin and glucose tolerance and, 21-22, 24

# HEXOSE

phosphorylation

and regulation of glucose metabolism in rat islets, 913-915

transport by fibroblasts

from diabetics and nondiabetics, 564, 566

# HEXOSE D-ALLOSE

transport in perfused skeletal muscle of genetically obese-diabetic mice and glucose metabolism studies, 215-216

# HISTAMINE

and microvessels of streptozotocin-diabetic Syrian hamsters, 97-98

# HISTOCOMPATIBILITY ANTIGENS

and lymphocytotoxic antigens

in juvenile-onset diabetics, 26-29

# HLA ANTIGENS

and viral antibody titers

in insulin-dependent juvenile diabetics and controls, 584-589

# HLA-DR4 ANTIGENS

and capillary basement membrane

width in parents of children with type I diabetes, 475-479

# HOMOCYSTINURIA

and endothelial injury

and platelet response, \*40

# HORMONES

counterregulatory

in insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628-629, 630-632

and growth of cultured rat islet tumor cells, 1022-1027

insulinotropic

response to glucose in normal and gestational diabetic pregnancy, 504-508

sex steroids

and expression of mutations at diabetic locus in male mice, 1036-1039

and skeletal muscle metabolism in rats, 545-550

# HYALURONIC ACID

in glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393-395

# HYDROGEN

production

and carbohydrate absorption study, 952, 953-954

# HYDROGEN CHLORIDE

intragastric, and splanchnic somatostatin release in dogs

insulin and, 735-738

# HYDROGEN IONS

in blood

in metabolic acidosis, 781-782

# $\beta$ -HYDROXY- $\beta$ -METHYLGLUTARYL-CoA REDUCTASE

and cholesterol metabolism studies in diabetic rats, \*79-81

# 3-HYDROXYBUTYRATE

effects on insulin binding and action in cultured human fibroblasts, 402-405

and exercise in diabetics and normals, 985-986

renal clearance of

in diabetic ketoacidosis, 510-517

# p-HYDROXYPHENETHYLBIGUANIDE

toxicity and hydroxylation study, 644-649

# HYPERCHLOREMIC ACIDOSIS

mechanism of

during recovery phases of diabetic ketoacidosis, 310-313

# HYPERCHOLESTEROLEMIA

arterial injury and

atherogenesis and, \*9

and coronary artery disease, \*4

in endothelial cell injury studies, \*40-41

and impaired endothelial cell migration, \*41

# HYPERGLUCAGONEMIA

and glycogenolysis and gluconeogenesis in dogs, 180-186

# HYPERGLYCEMIA

atherosclerosis and, \*2, \*49-53

and hyperinsulinemia, \*5

and blood clotting assays in diabetics, \*35

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



and blood glucose levels in genetically diabetic mice, 91  
and blood platelet survival in diabetics, 486-489  
control  
and measurement of glycosylated hemoglobins, 616  
2-deoxyglucose-induced  
and wound healing in mice, 407-410  
and increased dopamine- $\beta$ -hydroxylase activity in streptozotocin-diabetic rats, 418-419  
and insulin withdrawal in totally duodenopancreatectomized humans  
and somatostatin, 851-855  
and intestinal sugar flux in rats, 570  
islet mass and B-cell function loss preceding  
in mice given multiple low doses of streptozotocin, 424-429  
maternal  
and infant hyperglycemia, 271, 273  
and microangiopathy in cold-adapted eel, 317-325  
onset in mice after streptozotocin doses age and, 718-722  
in pregnant diabetics with insulin infusion pumps, 894  
streptozotocin-induced in neonatal rat islets, 64-69  
and sympathetic nervous system activity in normal man, 219-225  
and vascular volume, \*34

#### **HYPERINSULINEMIA**

and atherosclerosis, \*5  
and dietary control in diabetic mice, 109, 110  
and hypoglycemia in insulinemia patients, 377-380  
in non-insulin-dependent diabetics, \*2  
in obese offspring of obese parents, 14-18  
in prolonged glucose clamp studies and glucose utilization, 829-834  
and sympathetic nervous system activity in normal man, 219-225

#### **HYPERKALEMIA**

and diabetes  
and renin-angiotensin-aldosterone system, 335-339

#### **HYPERLIPIDEMIA**

and endothelial cell injury studies, \*40-41  
and hemostasis in diabetes, \*33-34

#### **HYPERPHAGIA**

and hypercholesterolemia in diabetic rats, \*80-81

#### **HYPERSOMATOSTATINEMIA**

of insulin deficiency  
and high plasma free fatty acid levels, 358-360

#### **HYPERTENSION**

and arterial stiffening, \*101  
and endothelial injury, \*2  
insulin and, 224-225  
in juvenile-onset insulin-dependent diabetics, 178  
as risk factor for renal and coronary heart disease  
in juvenile-onset diabetics, \*90-96, \*105

#### **HYPERTRIGLYCERIDEMIA**

and coronary artery disease, \*4-5  
diabetic  
in insulin-dependent and non-insulin-dependent diabetics and streptozotocin-diabetic and nondiabetic rats, \*66-74  
in rabbits  
triphenyltin fluoride-induced, 1013-1020

#### **HYPOALANINEMIA**

in pregnancy  
and skeletal muscle metabolism, 545-550

#### **HYPOGLUCAGONEMIA**

and liver glucose production in dogs, 490-494

#### **HYPOGLYCEMIA**

and diabetic pregnancy  
and insulin infusion pump, 893, 894, 895  
glucose recovery from  
adrenergic blockade and, 261-263  
hyperinsulinemia, and nesidioblastosis in neonates  
pancreatic somatostatin decrease and, 122-125  
idiopathic postabsorptive, 465-469  
insulin-induced in diabetics with and without autonomic neuropathy  
hormonal, metabolic, and cardiovascular responses to, 626-632  
in insulinoma patients:  
insulin suppression of hepatic glucose production and, 377-380  
postprandial  
diagnosis of, 996-999  
in pregnancy  
and skeletal muscle metabolism, 545-550

#### **HYPOPHOSPHATEMIA**

and insulin responses in dogs, 384

#### **HYPOTENSION**

postural  
in aldose reductase inhibition trial in diabetic neuropathy, 461

#### **HYPOXIA**

and endothelial cells and smooth muscle cells in low oxygen environment  
atherosclerosis and, \*41

#### **IBUPROFEN**

and inhibition of prostaglandin E synthesis in neonatal rat pancreatic cells  
insulin secretion and, 551-556

#### **IMMUNE COMPLEXES**

soluble, from diabetic serum  
platelet aggregation and ATP release after incubation with, 575-578

#### **IMMUNIZATION**

pneumococcal  
in adult diabetics, 119-121

#### **IMMUNOCYTOCHEMICAL STAINING STUDIES**

and pancreas islet A-, B-, and D-cell populations  
in postnatal rats, 813-817  
of pancreatic tissue from neonates with nesidioblastosis, 122-125

#### **IMMUNOFLUORESCENCE STUDIES**

of diabetogenic drug inhibition of superoxide dismutase, 236-237, 239-240  
and effects of streptozotocin on mouse pancreas  
age and, 719-720, 722  
of isolated mouse islets after incubation with serum from diabetic patients with complement-fixing islet cell antibodies, 1051-1056  
of kidney basement membrane albumin concentrations in diabetics and nondiabetics, 844-845  
of lymphocyte hybrid cells, 227  
of ratfish islet cells  
and glucagon immunoreactivity study, 192-195  
of renal cortex from diabetic mice  
dietary control and, 107, 108-111

#### **IMMUNOGLOBULIN**

and autoantibodies against insulin receptor study, 354-357

#### **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# IMMUNOGLOBULIN G

- and affinity chromatography, 471-472, 473-474
- extravasation into cerebral cortex of diabetic rats, 500-503
- stimulatory effect on adipocyte lipogenesis, 1068-1071
- transferrin clearance ratios
  - as index for protein excretion, 658, 659, 661, 662

# IMMUNOHISTOCHEMICAL STUDIES

- of plasma protein extravasation into cerebral cortex of diabetic rats, 500-503
- of rat islet tissues and adenomas from nicotinamide and streptozotocin-treated rats, 305-307

# IMMUNOLOGY

- and arterial injury, \*9, \*31
- and induction of complement-dependent antibody cytotoxic to cultured beta cells in mice, 30-38
- and pneumococcal immunization in adult diabetics, 119-121

# IMPOTENCE

- and aldose reductase inhibition in diabetic neuropathy, 461

# INDOMETHACIN

- and prostaglandin E synthesis by rat pancreas, 553

# INFANTS

- of diabetic mothers
  - immunocytochemical study of pancreatic specimens from, 271-273
  - and insulin infusion pump during pregnancy, 894-895
- with hypoglycemia, hyperinsulinemia and nesidioblastosis
  - and pancreatic somatostatin decrease, 122-125

# INFECTION, See also Wound healing and diabetes

- and pneumococcal immunization in adult diabetics, 119-121

# INSECTS

- Drosophila melanogaster*
  - insulin content, 70-75

# INSULIN

- action
  - and insulin receptor defects, 149
  - and postreceptor defects, 149-150
- action and response
  - in diabetic hypertriglyceridemia studies, \*67

# aggregation

- dicarboxylic amino acids and prevention of, 83-85

# antisera to

- and wound healing in mice, 407-410
- and arterial wall lipid metabolism in streptozotocin-diabetic rats, \*55

# assays

- of fetal pancreatic grafts in adult streptozotocin-diabetic rats, 10

# basal plasma

- brief, irregular oscillations of concentrations in diabetics, 435-439

# binding

- in different mouse skeletal muscles, 702-704

- by erythrocytes and monocytes in normal and disease states, 896-901

- wheat germ agglutinin-induced tissue differences in, 196-201

- binding, internalization, and insulin receptor regulation

- in fibroblasts from non-insulin-dependent diabetics, 596-600

- binding and action in cultured human fibroblasts

- effect of pH and 3-hydroxybutyrate on, 402-405

- from maturity-onset of the young diabetics, 940-945

- binding to isolated bovine brain microvessels, 757-761

# binding to lymphocytes

- inhibition by naturally occurring antireceptor antibodies, 979-981

# cardiotonic effects of, 224-225

- circulating hormonal and nonhormonal antagonists, 149

- content, synthesis, and glucose-induced secretion in cultured rat pancreatic islets

- myo-inositol concentrations and, 621-625

# content of rat pancreas

- during postnatal development, 814-816

# continuous subcutaneous infusion

- and exercise-induced microalbuminuria in insulin-dependent diabetic men, 818-822

# deficiency

- hypersomatostatinemia of, high plasma free fatty acid levels and, 358-360

- and increased sugar transport in streptozotocin-diabetic rats, 570-571

# delivery by artificial pancreas

- correlation between carbohydrate and, 101-105

# -dependent diabetics

- and albumin deposition in dermal capillary basement membrane, 275-278

- antibodies to nucleic acids in, 873-874

- continuous subcutaneous insulin infusion and correction of exercise-induced microalbuminuria in, 818-822

- dietary carbohydrate and insulin delivery by artificial pancreas in, 101-105

- high density lipoprotein composition in, 132-137

- and lipoprotein metabolism, \*88-89

- platelet arachidonic acid metabolism in, \*44-47

- prospective study of viral titers and HLA antigens in, 584-589

- in rats, and lymphocytic thyroiditis, 1058-1060

- Registry in Allegheny County, Pennsylvania, 279-283

- dependent juvenile diabetes

- effect of pubertal stage and recent blood glucose control on somatomedin C in, 868-871

- hypertension as risk factor for renal and coronary heart disease in, \*90-96

- long-term study of mortality and vascular complications, 175-178

- lymphocytotoxic antibodies and histocompatibility antigens in, 26-29

- dependent and nondependent diabetes and high density lipoprotein metabolism, \*84-86

# dosage

- and insulin infusion pump in pregnant diabetics, 892, 893-894

- and plasma somatomedin C in juvenile diabetics, pubertal stage and, 868-871

- dose-response kinetics for glucose disposal

- in insulin resistance studies in non-insulin-dependent diabetics, 990-992

- effect on arterial lesions, \*55

- effect on cultured monkey arterial cells, \*55-56

- fasting serum levels

- and body weight and skeletal muscle morphology and enzyme activity, 19-25

- gastrointestinal absorption in rats and sodium 5-methoxysalicylate, 1065-1066

# gene

- location of, 267-270

- and glomerular lesions in streptozotocin-diabetic rats, 111

- and glucagon levels in dogs exorphins and, 362-364

- oxytocin infusion and, 112-114

- and glucose infusions in normal man sympathetic nervous system activity and, 219-225

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# SUBJECT INDEX 1981

- and glucose and C-peptide response to glucagon injection
  - in mild and severe diabetics and normal subjects, 685-692
- glucose-stimulated release from isolated perfused rat pancreas
  - muscimol and, 168-170
- and glucose transport by cultured human fibroblasts, 523-528
- and glucose uptake and metabolism by skeletal muscle from genetically obese-diabetic mice, 214
- and glucose utilization during exercise in normal and diabetic subjects, 983-988
- and glycogen synthase and pyruvate dehydrogenase activities in skeletal muscle of genetically obese-diabetic mice, 216
- and glycolytic intermediary metabolism in erythrocytes during diabetic ketoacidosis, 346-352
- and hepatic fructose 2,6-bisphosphate levels in alloxan-diabetic starved rats, 1062-1064
- and hepatic glucose production
  - and suppression of hypoglycemia in insulinoma patients, 377-380
- and high-density lipoprotein metabolism, \*83-84
- highly purified porcine compared with highly purified bovine and conventional insulins
  - tissue sensitivity studies in diabetics, 650-655
- and hyperphagia
  - and hypercholesterolemia, \*80-81
- immunoreactive
  - in diabetic and normal mice, 108, 110
  - effect of islet-activating protein on secretion of, 430-434
- incomplete conversion of proinsulin to, 148
- induced hypoglycemia in diabetics
  - with and without autonomic neuropathy
  - hormonal, metabolic, and cardiovascular responses to, 626-632
- induced insulin resistance in vitro, 155-157
- induced receptor loss and insulin internalization
  - in isolated rat adipocytes, 746-752
- infusion
  - with long-term continuous intraperitoneal insulin infusion device, 1073-1074
- in insects and annelids, 70-75
- and insulin secretagogues effects on calcium-dependent phosphatidylinositol breakdown and amylase secretion in rat pancreas, 396-401
- and intravenous glucose disposal
  - indirect calorimetry and hepatic and femoral venous catheterization in study of, 1000-1006
- and iodotyrosine metabolism
  - in streptozotocin-diabetic rats, 697-698
- levels in hypoglucagonemic dogs
  - liver glucose production and, 491-492
- like growth factor
  - and glucose transport by cultured human fibroblasts, 523-528
- liver and pancreas content
  - in pancreatic islet allograft survival study, 947-948
- open-loop administration in severely insulin-deficient patients
  - waveform requirements study, 710-716
- and ornithine decarboxylase regulation in rat skeletal muscle, 682-683
- pancreatic content
  - in infants of diabetic mothers, 271-273
- and protein- and acid-induced splanchnic somatostatin release in dogs, 735-738
- and rat aorta 6-oxo-prostaglandin  $F_{1\alpha}$  production, 935-938
- and rat islet tumor growth in serum-free medium, 1022-1027
- recombined A and B-chains of synthetic human and pancreatic pork
  - immunologic potency of, 265-266
- release
  - glucose, glucagon, and arginine-stimulated, in triphenyltin fluoride-treated rabbits, 1016-1017
  - and glucose and acetylcholine effects on electrical activity in pancreatic islet cell membrane, 558-561
  - glucose- and arginine-induced, in cristine and, 539-544
  - glucose-stimulated, trifluoperazine sites of action in inhibition of, 960-966
  - and glucose stimulation of calcium in rat pancreatic islets, 52-54
  - from islet tissues and adenomas of rats treated with nicotinamide and streptozotocin, 302-308
  - 3-isobutyl-1-methyl-xanthine priming effect in isolated rat islets of Langerhans, 754-756
  - from isolated mouse islets, and incubation with complement-fixing islet cell antibodies from diabetics, 1051-1056
  - in rat pancreatic islets during fasting and refeeding, 923-928
  - in study of regulation of glucose metabolism in rat pancreatic islets, 917-918
  - release from column-perfused rat pancreatic B-cells
- islet cell surface antibodies and complement and, 231-234
- and renal hypertrophy in diabetic animals, 485
- requirements
  - in postpancreatectomy patients, 641-642
- resistance
  - assessment with insulin suppression test and euglycemic clamp, 387-392
  - causes of, 148-151
  - and circulating insulin antagonists, 149
  - epinephrine-propranolol infusions for measurement of, cardiac arrhythmias during, 618-620
  - and hyperinsulinemia in non-insulin-dependent diabetics, \*2
  - insulin antibody-mediated, and semisynthetic insulin analogues, 519-522
  - and insulin binding to erythrocytes and monocytes, 900
  - insulin-induced in vitro, 155-157
  - in non-insulin-dependent diabetics, 157-160, 990-995
  - in non-insulin-dependent diabetics, fibroblast studies and, 562-566
  - in obesity, 151-155
  - and post-receptor defects, 149-151
  - in pregnancy, skeletal muscle metabolisms and, 545-550
  - resistance and action in vitro and in vivo, 148-161
- response to glucose
  - and colchicine, 1008-1012
  - in normal and gestational-diabetic pregnancy, 504-508
- response to high glucose and arginine in neonatal rat model for non-insulin-dependent diabetes, 591, 594
- responses
  - and subcutaneous, isogeneic transplantation of duct-ligated pancreas in diabetic mice, 857-863
- role in atherosclerosis
  - in diabetics and nondiabetics, \*54-57
- secretion
  - colchicine and, 1008-1012
  - and 1,25 dihydroxyvitamin  $D_3$  in Vitamin D-deficient rats, 382-385
  - from fetal mouse pancreas, effect of culture conditions on, 804-811
  - glucose-induced, in fetal and neonatal rat, 56-62
  - by islets from new animal model for non-insulin-dependent diabetes, 590-594
  - from isolated, perfused rat pancreas, glucose and cyclic AMP and, 40-44
  - in perfused rat pancreas, ethanol, acetaldehyde, and acetate

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

and, 704-708  
and prostaglandin E synthesis in neonatal rat pancreas, 551-556  
somatostatin suppression of, portal vein hormone measurements and, 664-668  
veratridine and calcium and, 446-449  
secretion from isolated rat islets age and, 77-82  
prostacyclin and 6-keto-prostaglandin  $F_{1\alpha}$  and, 824-827  
zinc-induced inhibition of, 341-344  
secretion rates in normal subjects correlation with urinary C-peptide excretion, 639-642  
semisynthetic analogues with different amino acids immunoreactivity and biological activity of, 519-522  
sensitivity in skeletal muscle of genetically obese mice, 211-217  
and streptozotocin diabetes in rats adipose tissue cyclic AMP phosphodiesterase and protein activator and, 372-375  
synthesis by recombinant DNA methodology, 265-266  
therapy and insulin resistance in type II diabetics, diabetes classifications and, 739-744  
and pancreatic somatostatin secretion abnormalities in streptozotocin-diabetic rats, 865-867  
in streptozotocin-diabetic rats, regional localization of cerebral edema following, 762-766  
-treated diabetics and polymorphonuclear leukocytes-stimulated glucose oxidation and iodination in, 256-259  
treatment of streptozotocin-diabetic Syrian hamsters and microvascular studies, 95, 98, 100  
uptake of kidney, 929-933

# **INSULIN-DEPENDENT DIABETES MELLITUS REGISTRY, 279-283**

## **INSULIN INFUSION SYSTEMS**

in diabetic pregnancy, 891-895  
long-term continuous intraperitoneal, 1073-1074

## **INSULIN RECEPTORS**

absence on resting lymphocytes, 314-316  
antibodies against, 149  
autoantibodies against mechanism of, 354-357  
and simultaneously occurring autoan-

tibodies against somatomedin-C receptors, 979-981  
and binding potency of recombinant synthetic human and pancreatic port insulins, 265-266  
on bovine brain microvessels, 757-761  
cryptic and hypertonic salt solutions or enzymatic digestion of lymphocytes, 314-416  
defects, 149  
erythrocyte disappearance during maturation in sheep, 411-414  
of erythrocytes and monocytes in normal and disease states in man, 896-901  
in fibroblasts from non-insulin-dependent diabetics insulin regulation and, 596-600  
insulin-induced loss in isolated rat adipocytes and internalization of insulin receptors, 746-752  
and insulin resistance in non-insulin-dependent diabetics, 990-995  
membrane lipid environment effects on, 773-779  
in rat adipocytes and hepatocytes and human lymphocytes  $^{125}$ I-insulin binding in, 4-5  
tissue differences in, 196-201

## **INSULIN SUPPRESSION TEST**

assessment of insulin resistance with, 387-392

## **INSULIN TOLERANCE TESTS**

and triphenyltin fluoride in rabbits, 1017

## **$^{125}$ I-INSULIN**

and autoantibodies against insulin receptor study, 354-357  
binding to capillaries from bovine cerebral cortex, 757-761  
in insulin binding studies in fibroblasts from non-insulin-dependent diabetics, 596-600  
preparation, biologic properties and long-term stability, 1-8  
tyrosine A14 [ $^{125}$ I]monoiodoinsulin, 1-8

## **INSULINOMA**

and hypoglycemia and insulin suppression of hepatic glucose production, 377-380  
and insulin binding by erythrocytes and monocytes, 896-901

## **INTERMITTENT CLAUDICATION SYNDROME**

in diabetics, \*49-50

## **IDOACETATE**

and renal insulin uptake, 930-933

## **IODOTYRONINE**

metabolism in diabetic rats, 694-698

## **ISLET-ACTIVATING PROTEIN**

and immunoreactive insulin and glucagon secretion in normal, alloxan-treated, and depancreatized dogs, 430-434

## **ISLETS OF LANGERHANS. See also**

Pancreas islets  
D-cells somatostatin production diabetes and, 188  
inhibition of superoxide dismutase by diabetogenic drugs, 236-240  
isolated perfused mouse and glucose and acetylcholine effects on electrical activity in, 558-561  
isolated rat 3-isobutyl-1-methyl-xanthine priming effect on insulin release in, 754-756  
zinc-induced inhibition of insulin secretion from, 341-344

## **3-ISOBUTYL-1-METHYL-XANTHINE**

and insulin release in isolated rat islets of Langerhans, 754-756  
and prostaglandin inhibition of insulin secretion in isolated rat islets, 826-827

## **ISONIAZID**

acetylation and slow and fast acetylators, peripheral neuropathy and, 907

## **ISOPROTERENOL**

and insulin secretion by islets from new animal model for non-insulin-dependent diabetes, 591-592, 594

## **J**

## **JAPANESE**

diabetics atherosclerosis incidence in, \*1

## **JUVENILE DIABETES**

and capillary basement membrane width and HLA antigens in parents of type 1, 475-479  
and continuous central venous insulin infusion waveform requirements for metabolic normalization, 710-716

## **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

insulin-dependent  
 effects of pubertal stage and recent  
 blood glucose control on  
 plasma somatomedin C in, 868-  
 871  
 hypertension as risk factor for renal  
 and coronary heart disease in,  
 \*90-96  
 prospective study of viral titers and  
 HLA antigens in, 584-589  
 insulin requirements, 642  
 mortality and vascular complications  
 long-term study, 175-178

## K

### KETOACIDOSIS, DIABETIC

and erythrocytes glycolytic intermediary  
 metabolism, 346-352  
 mechanism of hyperchloremic acidosis  
 during recovery phase of, 310-  
 313  
 mortality and, 1  
 pathophysiological aspects of, 781-786  
 renal function and effects of partial re-  
 hydration during, 510-517

### KETOAMINE

-linked glucose  
 in collagen of glomerular basement  
 membrane from diabetic rats,  
 616

### KETONE BODIES

and acid-base balance, 517  
 anion concentration in diabetic ketoaci-  
 dosis, 782-783  
 renal handling during diabetic ketoaci-  
 dosis, 516-517  
 urinary excretion in diabetic ketoaci-  
 dosis, 510-511

### 6-KETO-PROSTAGLANDIN F<sub>1α</sub>

and insulin secretion and cyclic AMP  
 content of rat isolated islets,  
 824-827

### KIDNEY

basement membrane  
 albumin concentrations in diabetes,  
 843-845  
 clearance of specific plasma proteins  
 diabetes duration and, 656-662  
 of diabetic and normal Chinese ham-  
 sters  
 analysis of glycosaminoglycan from,  
 393-395  
 disease  
 hypertension as risk factor in insulin-  
 dependent juvenile diabetes for,  
 \*90-96

function  
 and partial rehydration during dia-  
 betic ketoacidosis, 510-517  
 and subcutaneous insulin infusion in  
 insulin-dependent diabetics, ex-  
 ercise-induced microalbumin-  
 uria and, 818-822  
 glomerular basement membrane accu-  
 mulation in streptozotocin-dia-  
 betic rats  
 islet cell transplantation and, 481-  
 485  
 glomerular lesions in streptozotocin-dia-  
 betic rats  
 insulin or pancreatic transplantation  
 and, 111  
 growth  
 and streptozotocin-induced diabetes,  
 484  
 insulin uptake, 929-933  
 nephropathy  
 dietary control and prevention in dia-  
 betic mice of, 106-111  
 rat glomerular basement membrane  
 nonenzymatic glycosylation of, 367-  
 370  
 reabsorption and excretion rates of ke-  
 tone bodies  
 in diabetic ketoacidosis, 516-517  
 tubular basement membrane  
 albumin content in diabetes, 843-845

## L

### LACTATE DEHYDROGENASE

in gastrocnemius muscle tissue  
 fasting serum insulin and glucose tol-  
 erance and, 21-22, 24

### LECTIN. See Wheat germ agglutinin

### "LEPRECHAUNISM"

and beta-cell hyperplasia, 150

### LESIONS

arterial  
 insulin effect on, \*55  
 atherosclerotic  
 and injury to arterial wall, \*8-12  
 encephalomyocarditis-induced in  
 mouse pancreas islets  
 genetic obesity and, 451-454  
 glomerular  
 in streptozotocin-diabetic rats, insulin  
 or pancreatic transplantation  
 and, 111

### LEUKOCYTES. See also Mononuclear

leukocytes  
 and contamination of islet allograft  
 preparations, 242-246  
 and immune rejection in transplants,  
 285-290

polymorphonuclear  
 from insulin-treated diabetics, de-  
 creased stimulated glucose oxi-  
 dation and iodination by, 256-  
 259

### LINOLEATE

-enrichment of Friend erythroleukemia  
 cells media  
 effects on insulin receptors, 773-779

### LIPIDS

accumulation in atherosclerotic lesions  
 induced in rabbit aorta, \*12  
 metabolism  
 in cultured rat arterial smooth muscle  
 cells, insulin and, \*56-57  
 and endothelial cell biology, \*19-22  
 in streptozotocin-diabetic rat arteries,  
 \*55

### LIPOGENESIS

adipocyte  
 immunoglobulin G stimulatory effect  
 on, 1068-1071  
 and insulin-induced hypoglycemia  
 in diabetics with and without autono-  
 mic neuropathy, 628, 630-631  
 norepinephrine-induced in isolated rat  
 adipocytes  
 prostacyclin production and, 163-166

### LIPOPROTEIN LIPASE

of adipose tissue  
 in obese diabetics and nondiabetics,  
 \*86  
 in gastrocnemius muscle tissue  
 fasting serum insulin and glucose in-  
 tolerance and, 21-22, 24  
 and triphenyltin fluoride treatment in  
 rabbits, 1016, 1017-1018

### LIPOPROTEINS

and atherogenesis in diabetics, \*4-5  
 endothelial cell biology, \*19-22  
 epithelial cell block to interiorization of,  
 \*20-21  
 high-density  
 alterations by cholesterol feeding, \*62  
 -63  
 composition in insulin-dependent dia-  
 betics, 132-137  
 and diabetes, \*5, \*82-86  
 and diabetic atherosclerosis, \*86  
 metabolism of, \*82-86  
 low-density  
 atherosclerosis incidence and, \*19,  
 \*88  
 and endothelial damage, \*2  
 and high fat-high cholesterol diets,  
 \*64  
 nonenzymatic glycosylation studies,  
 875-877

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113



metabolism  
in atherosclerosis, \*60-65  
in diabetes, \*88-89  
and dietary alteration of degree of  
sialylation of ApoC-III, 530-533  
and hyperinsulinemia, \*5  
patterns  
in obese children of obese parents,  
15-17  
triglyceride-rich  
endothelial cell uptake of, \*21-22  
uptake into arterial smooth muscle  
cells, \*5  
very-low-density  
plasma removal of, 496-499  
very-low-density remnant  
atherogenesis in diabetes and, \*4-5  
very-low-density-triglyceride secretion  
rate  
in diabetic hypertriglyceridemia,  
\*67  
 *$\beta$* -very-low-density  
and origins of cholesterol-accumulat-  
ing foam cells in arterial walls,  
\*63-64

# LIVER

extraction of plasma immunoreactive  
glucagon components in dogs,  
767-779  
glucose production  
and glucagon deficiency in dogs,  
490-494  
glucose production in insulinoma pa-  
tients  
insulin therapy and, 377-380  
glycogenolysis and gluconeogenesis in  
conscious dog  
glucagon and, 180-186  
and iodotyronine metabolism  
in diabetic rats, 694-698  
mean fractional insulin extraction  
and calculation of insulin secretion  
rates in normal subjects, 639-  
642  
mitochondria  
inhibition of superoxide dismutase by  
diabetogenic drugs, 236-240  
rat  
fructose 2,6-bisphosphate levels, ef-  
fects of diabetes, insulin, starva-  
tion and refeeding on, 1062-  
1064  
insulin binding studies, 196-201  
and secretion of  *$\beta$* -very-low-density lipo-  
proteins, \*63-64  
and transplantation of islet xenografts  
into diabetic mice via portal  
vein, 285-290  
triglyceride secretion  
in streptozotocin-diabetic rats, \*68  
venous catheter technique  
and effect of insulin on intravenous  
glucose disposal, 1000-1006

and intravenous glucose disposal and  
insulin study, 1000-1006

# LYMPH

flow rate and triglyceride levels in tho-  
racic duct of normal and vagoto-  
mized dogs  
somatostatin and, 440-444

# LYMPHOCYTES

B- and T-cell  
in spontaneously diabetic rats, 887-  
889  
cultured human  
and autoantibodies against insulin re-  
ceptor studies, 354-357  
<sup>125</sup>I-insulin binding in, 4-5  
cultured human IM-9  
simultaneous inhibition of insulin  
and somatomedin-C binding to,  
979-981  
infiltration of pancreatic islets  
and multiple low doses of streptozoto-  
cin in mice, 424-429  
mice  
hybrid cell antibodies reacting with  
rat islet cell membrane anti-  
gens, 226-230  
and rejection of islet xenografts in dia-  
betic mice, 285-290  
stimulated and resting  
and insulin receptors, 314-316  
T-cell  
and rejection of established islet al-  
lografts, 242-246

# LYMPHOID CELLS

and islet xenograft survival, 285-290

# LYSINE ACETYSALICYLATE

and colchicine inhibition of insulin se-  
cretion, 1010-1012

# M

# MACROANGIOPATHY, DIABETIC

and endothelial cells of large and small  
vessels, \*24-27  
growth hormone and, \*14-16

# MACROPHAGES

and atherosclerotic lesions, \*63, \*64

# MAGE VALUES

and insulin infusion pump in pregnant  
diabetics, 894-895

# MANNOHEPTULOSE

and glucose- and glyceraldehyde-in-  
duced somatostatin, insulin and  
glucagon release by pancreatic  
D-cells, 207

# MAREK'S DISEASE

in chickens  
and atherosclerosis, \*29-31

# MENSTRUAL CYCLE

and erythrocyte and monocyte insulin  
binding, 901

# METABOLISM

arterial wall  
and atherogenesis, \*5  
cartilage and bone proteoglycans bio-  
synthesis  
in streptozotocin-diabetic rats, 670-  
677  
cholesterol  
in diabetes, role of diet in, \*76-81  
in endothelial cells, \*20  
composite energy, in peripheral nerve  
axons and Schwann cells  
in alloxan-diabetic rabbits, 967-974  
exercise-induced microalbuminuria in  
insulin-dependent diabetics  
continuous subcutaneous insulin infu-  
sion and, 818-822  
glucose  
in genetically obese-diabetic mice,  
211-217  
and prolonged glucose clamp stud-  
ies, 829-834  
in rat pancreatic islets, and adapta-  
tion of glycolytic enzymes to  
starving and refeeding, 923-928  
regulation in rat pancreas islets, 911-  
922  
glucose counterregulation in man, 261-  
263  
glucose metabolic clearance rate  
models, 847-850  
glycolytic intermediary in erythrocytes  
and diabetic ketoacidosis, 346-352  
of high density lipoproteins, \*82-83  
insulin and, \*83-84  
in insulin-dependent diabetes, \*84-  
85  
in non-insulin-dependent diabetics,  
\*85-86  
insulin, glucagon, and glucose  
and oxytocin infusions in normal  
dogs, 112-114  
insulin uptake by kidney, 929-933  
iodotyronine  
in streptozotocin-diabetic rats, 694-  
698  
lipid  
in cultured rat arterial smooth muscle  
cells, insulin and, \*56-57  
and endothelial cell biology, \*19-22  
lipoprotein  
in atherosclerosis, \*60-65  
in diabetes, \*88-89  
plasma glucose utilization and glucose  
clearance in normal man  
effects of plasma glucose concentra-  
tion on, 535-537

# DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

platelet arachidonic acid  
in diabetics, \*44-47  
rat skeletal muscle  
effects of pregnancy and sex steroids  
on, 545-550

### 3-O-METHYL-D-GLUCOSE

transport across ocular barriers in streptozotocin-diabetic rats, 903-905

### MICE

diabetic  
prolongation of islet xenograft survival  
in, 285-290  
expression of mutations at diabetic  
locus in  
and male lethal syndrome, 1035-1043  
genetically diabetic  
diet control and prevention of dia-  
betic nephropathy in, 106-111  
and H-2 haplotype and sex, 1029-  
1034  
platelet aggregation in cerebral and  
mesenteric microcirculation, 89-  
92  
genetically obese  
and encephalomyocarditis-virus-in-  
duced diabetes, 451-454  
genetically obese-diabetic  
hormone regulation of glucose metab-  
olism in, 211-217  
injection of complement-dependent islet  
cell antibodies into, 30-38  
islets  
incubated with serum from diabetic  
patients with complement-fixing  
islet cell antibodies, 1051-1056  
lymphocyte hybrid cell antibodies  
reaction with rat islet cell membrane  
antigens, 226-230  
and multiple low doses of streptozoto-  
cin  
islet mass and B-cell function loss  
preceding hyperglycemia in,  
424-429  
normal and genetically obese  
effect of sucrose overfeeding on Na,  
K-ATPase-mediated potassium  
uptake in, 975-978  
perfused, isolated islets of Langerhans  
effects of glucose and acetylcholine  
on electrical activity in, 558-  
561  
skeletal muscles  
insulin binding and glucose uptake  
differences in different types of,  
702-704  
streptozotocin damage and age study,  
718-722  
and streptozotocin-diabetes induced with  
multiple low doses of streptozo-  
tocin  
and exogenous superoxide dismu-  
tase, 634-638

streptozotocin-diabetic  
subcutaneous, isogeneic transplants  
of duct-ligated pancreas,  
glucose tolerance studies in,  
857-863  
wound healing in  
effect of antisera to insulin, 2-deoxy-  
glucose-induced hyperglyce-  
mia, and starvation on, 407-410

### MICROANGIOPATHY, DIABETIC

and endothelial cells of large and small  
vessels, \*24-27  
and enhanced platelet aggregation and  
soluble immune complexes from  
diabetic serum, 575-578  
and hyperglycemia in cold-adapted eel,  
317-325  
and microvascular alterations in strepto-  
zotocin-diabetic Syrian ham-  
sters, 93-100

### MICROSCOPY

of coronary arteries from cholesterol-fed  
miniature swine, \*60, \*61  
electron and beta-cell necrosis in dia-  
betic mice, 663  
and capillary basement membrane  
width study in parents of chil-  
dren with type 1 diabetes, 475-  
479  
and demonstration of glucagon in  
human fetal stomach, 879-882  
of kidneys from islet cell transplanted  
streptozotocin-diabetic rats, 482  
-485  
and microthrombus formation in reti-  
nal vessels in streptozotocin-di-  
abetic rats, 601-606  
of pancreas B-cell microtubular struc-  
tures, vincristine effects on glu-  
cose-induced insulin release  
and, 539-544  
of rabbit beta cells after triphenyltin  
fluoride treatment, 1017  
electron and transmission  
of blood capillaries of cold-adapted  
eels, 318, 319-322  
immunofluorescence  
of dermal capillary basement mem-  
brane of insulin-dependent dia-  
betics, albumin deposition in,  
275-278  
in microvessel studies of streptozoto-  
cin-diabetic Syrian hamsters, 94  
-100  
of injured rabbit aorta and atheroscle-  
rotic lesions, \*8  
light  
of fetal mouse pancreas in organ cul-  
ture effects study, 807  
in islet xenograft survival study in dia-  
betic mice, 285, 286, 288-290  
of kidneys from islet-cell transplanted  
streptozotocin-diabetic rats, 482

of mouse pancreas after induction of  
complement-dependent anti-  
body cytotoxicity to cultured  
beta cells, 33-38  
of pancreatic islet allografts after  
blood transfusion and ALS treat-  
ment in rats, 948, 949  
and renal histology in diabetic mice,  
107, 108, 109-111  
of skeletal muscle capillaries of dia-  
betics, 327, 330-331  
of streptozotocin-diabetic rat cartilage  
and bone, 672, 673  
light and electron  
of neonatal pig pseudo-islets, 580-  
583  
light and immunocytochemical  
and effects of streptozotocin on islet  
cells in rats, 426, 428-429  
mouse islets  
and diabetes gene expression, 1031-  
1032  
of mouse pancreas  
and age related to streptozotocin  
damage, 719-720, 722  
of nesidioblastic pancreas, 123, 124-  
125  
of pancreas islets  
of new strain of genetically obese-hy-  
perglycemic rats, 1047, 1049  
of pancreatic specimens from infants of  
diabetic mothers, 271-273  
of ratfish islet cells  
in glucagon immunoreactivity study,  
193-194  
of thyroid glands of rats with insulin-de-  
pendent diabetes and lympho-  
cytic thyroiditis, 1059

### MICROVASCULAR DISEASE

and insulin-dependent diabetes acetyla-  
tor dimorphism in, 907-909

**MINERALS.** See Calcium; Potassium;  
Zinc

### MONKEYS

cultured arterial cells  
insulin effects on, \*55-56

### MONOCYTES

insulin binding by  
and insulin resistant non-insulin-de-  
pendent diabetics, 990-995  
insulin binding in normal and disease  
states, 896-901

### MONONUCLEAR LEUKOCYTES

somatostatin and glucagon binding  
identification in humans, 127-131

### DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

**MONTREAL**

prospective study of viral antibody titers and HLA antigens in juvenile diabetics from, 584-589

**MORTALITY**

from atherosclerosis in diabetics and nondiabetics, \*1  
cardiovascular and diabetes, \*50-52  
causes in diabetics and nondiabetics, 327  
and diabetes gene expression in mice, 1031  
and hypertension in insulin-dependent juvenile-onset diabetics, \*90-96  
and juvenile diabetes long-term study, 177  
and male lethal diabetes syndrome in CBA/Lt mice, 1035-1043  
and neonatal nesidioblastosis pancreatic somatostatin and, 122-125  
and pneumonia in diabetics pneumococcal immunization and, 119-121

**MUSCIMOL**

glucose-stimulated somatostatin and insulin release from isolated, perfused rat pancreas, 168-170

**MUSCLE**

arterial smooth cells growth in diabetics, \*4  
proliferation, and endothelial injury, \*3  
capillary basement membrane width in parents of children with type 1 diabetes, 475-479  
gastrocnemius enzyme activities related to body weight, fasting serum insulin, and glucose tolerance, 19-25  
and insulin stimulation of glucose metabolism, 1000-1006  
skeletal capillaries of, in diabetics, 326-333  
effects of pregnancy and sex steroids on metabolism in, 545-550  
of genetically obese-diabetic mice, glucose metabolism in, 211-217  
insulin binding and glucose uptake in different types of, 702-704  
ornithine decarboxylase regulation, in fed and starved diabetic rats, 678-683

**MYELIN**

peripheral nerve proteolysis in streptozotocin-diabetic rats, 292-294

**MYELOMA**

immunoglobulin G and adipocyte lipogenesis study, 1068-1071

**MYOCARDIAL INFARCTION**

and atherosclerosis, \*39

**MYO-INOSITOL**

concentrations in cultured rat islets effects on insulin content, synthesis, glucose-induced secretion, and incorporation of <sup>3</sup>H-thymidine into DNA, 621-625  
and symptomatic polyneuropathy in diabetics comparison of clinical course and sequential electrophysiological test results, 139-147

**N**

**NALOXONE**

infusion during digested and undigested gluten meal in dogs plasma insulin and glucagon levels and, 363-364

**NEPHROPATHY**

in diabetic mice diet control and prevention of, 106-111

**NERVE GROWTH FACTOR**

rapid axonal transport in diabetic rats, 797-802

**NERVOUS SYSTEM**

central glucose requirements, 261  
energy metabolism in peripheral nerve axons and Schwann cells in alloxan diabetic rabbits, 967-974  
motor nerve conduction velocity and aldose reductase inhibition in diabetic neuropathy, 460-463  
peripheral nerve myelin abnormalities in streptozotocin-diabetic rats, 292-294  
rapid axonal transport of proteins in streptozotocin-diabetic rats, 797-802  
sympathetic insulin and glucose infusions and activities in normal man of, 219-225  
sympathoadrenal, in diabetic rats increased plasma dopamine- $\beta$ -hydroxylase and, 419-420

**NESIDIOBLASTOSIS**

neonatal decrease of pancreatic somatostatin in, 122-125

**NEUROPATHY, DIABETIC**

autonomic hormonal, metabolic, and cardiovascular responses to insulin-induced hypoglycemia in juvenile-onset diabetics with, 626-632  
and composite energy metabolism in peripheral nerve axons and Schwann cells in diabetic rabbits, 967-974  
peripheral clinical trial of Alrestatin in, 459-463  
and sciatic nerve retrograde transport of proteins in diabetic rats, 797-802  
symptomatic polyneuropathy and comparison of clinical course and sequential electrophysiological test results in therapeutic trials with myo-inositol, 139-147

**NEUTROPHIL IODINATION REACTION**

in diabetics, 258-259

**NICOTINAMIDE**

and streptozotocin-treated rats insulin release from islet tissue and adenomas of, 302-308

**NICOTINIC ACID**

-induced lowering of plasma free fatty acids and hypersomatostatinemia of insulin deficiency in dogs, 358-360

**NOREPINEPHRINE**

-induced lipolysis in isolated rat adipocytes, prostacyclin production during, 163-166  
and microvessels of streptozotocin-diabetic Syrian hamsters, 96  
responses to glucose and insulin infusion in normal man, 219-225

**NUCLEIC ACIDS. See also DNA**

antibodies in insulin-dependent diabetics and unaffected relatives, 873-874

**NUTRITION**

and continuous central venous insulin infusion waveform studies in juvenile diabetics, 712-716  
plasma somatostatin-like immunoreactivity before and after mixed meal, 883-885  
role of somatostatin in homeostasis and, 883-885

**O**

**OBESITY**

and atherosclerosis and diabetes, \*1

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

and diabetes gene expression in mice, 1029-1030  
 and diabetes in mice  
     and hormone regulation of glucose metabolism, 211-217  
 and effects of sucrose overfeeding on Na, K-ATPase-mediated potassium uptake in mice, 975-978  
 familial  
     and hyperinsulinism in adults and offspring, 14-17  
 and glucose utilization during glucose clamp studies, 829-834  
 and hypertension in diabetics and endothelial injury, \*2  
 and hypertriglyceridemia  
     and insulin resistance and hyperinsulinemia, \*4-5  
 insulin resistance in, 151-155  
 and lipoprotein lipase  
     in diabetics and nondiabetics, \*86  
 in mice  
     effect on encephalomyocarditis virus-induced diabetes, 451-454  
 and new strain of diabetic rat, 1045-1049  
 and skeletal muscle related to glucose intolerance and insulin resistance, 19-25

**OLEATE**

-enrichment of Friend erythroleukemia cells media  
 effects on insulin receptors, 773-779

**OPHTHALMOSCOPY**

and clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460

**ORGANOGENESIS**

in streptozotocin-diabetic rats  
 and prevention of congenital lumbosacral defects in offspring, 965-969

**ORNITHINE DECARBOXYLASE**

regulation in skeletal muscle of diabetic fed and starved rats, 678-683

**OUABAIN**

and renal insulin uptake, 930-933  
 and veratridine-induced glucagon and insulin secretion from rat pancreas, 448, 449

**OVARIECTOMY**

and expression of mutations at diabetic locus in female mice, 1037-1039

**OVARIES**

steroids  
 and expression of mutations at diabetic locus in male mice, 1035-1039

**OXIDATIVE SULFITYLATION**

of <sup>125</sup>I-insulin, 2

**6-OXO-PROSTAGLANDIN F<sub>1α</sub>**

production by rat aorta  
 and diabetes, insulin treatment, and caloric deprivation, 935-938

**OXYTOCIN**

infusion in normal dogs  
 plasma insulin and glucagon levels and glucose production and uptake and, 112-114

**P**

**PANCREAS. See also Artificial pancreas**

A-, B-, and D-cell populations during postnatal development in rat, 813-817  
 abnormal beta-cell secretory product, 148-149  
 and basal plasma insulin and glucose concentrations in diabetic man, 435-439  
 B-cell function  
     vitamin D and, 382-385  
 B-cell microtubular structures and vincristine effect on glucose-induced insulin release from rat pancreas, 539-544  
 B-cell regeneration in streptozotocin-treated neonatal rats, 64-69  
 beta cells  
     immune lysis induced in mice, 30-38  
 bioartificial  
     in streptozotocin-diabetic rats, 296-301  
 D-cell  
     recognition of D-glucose, 203-209  
 dog islet cells  
     new method of preparation, 455-458  
 duct-ligated, subcutaneous isogeneic transplantation in diabetic mice  
     glucose tolerance studies on, 857-863  
 fetal mouse  
     organ culture conditions effect on insulin and glucagon secretion, 804-811  
 fetal and neonatal rat  
     glucose-induced insulin secretion in, 56-62  
 glucagon  
     response to oral glucose in normal and gestational-diabetic pregnancy, 504-508  
     transformation of glucagon-like immunoreactivity of pig gut into, 792-794  
 glucagon and insulin content in mice

and streptozotocin and superoxide dismutase, 634-638  
 of infants of diabetic mothers  
     insulin, glucagon, somatostatin, and pancreatic polypeptide in, 271-273  
 insulin biosynthesis, 148  
 and insulin resistance, 148  
 islet allografts transplantation  
     cellular stimuli for rejection of, 242-246  
     donor strain ACI blood transfusions and ALS therapy and survival of, 947-950  
 islet cell antibodies  
     from diabetics, alterations in insulin release in vitro by, 1051-1056  
     induced in mice, 30-38  
 islet cell intraportal transplantation in streptozotocin-diabetic rats  
     kidney hypertrophy and glomerular basement membrane accumulation after, 481-485  
 islet cell membrane electrical activity  
     glucose and acetylcholine and, 558-561  
 islet histology  
     and streptozotocin effects in mice, age and, 719-720, 722  
 islet mass and B-cell function loss preceding hyperglycemia  
     in mice given multiple low doses of streptozotocin, 424-429  
 islet secretion studies  
     in neonatal rat model for non-insulin-dependent diabetes, 590-594  
 islet tumor cells  
     hormones and factors stimulating growth of, 1022-1027  
 islets  
     of genetically obese and lean mice, encephalomyocarditis virus-induced diabetes and, 451-454  
 isolated perfused rat  
     effect of muscimol on glucose-stimulated somatostatin and insulin release from, 168-170  
     glucose and cyclic AMP and somatostatin and insulin secretion in, 40-44  
 isolated rat islets  
     age and proinsulin and insulin secretion from, 77-82  
     in bioartificial pancreas, 296-301  
     prostacyclin and 6-keto-prostaglandin F<sub>1α</sub> effects on insulin secretion and cyclic AMP content in, 824-827  
 mouse islets  
     incubated with serum from diabetic patients with complement-fixing islet cell antibodies, 1051-1056  
 neonatal porcine  
     and formation of pseudo islets, 580-583

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113



neonatal rat  
and prostaglandin E synthesis and insulin secretion, 551-556

neonatal rat islets  
streptozotocin and, 64-69

newborn rat monolayer cultures  
effects of veratridine and calcium on glucagon and insulin secretion from, 446-449

rabbit beta cells  
and triphenyltin fluoride-inhibition of insulin secretion, diabetic lipemia and, 1013-1020

rat  
effects of insulin and insulin secretagogues on calcium-dependent phosphatidylinositol breakdown and amylase secretion in, 396-401

ethanol, acetaldehyde, and acetate effects on glucose-induced insulin and glucagon secretion in, 705-708

vincristine and glucose- and arginine-induced insulin release and glucose tolerance in, 539-544

rat fetal  
transplantation into adult diabetic rats, 9-12

rat islet B-cells  
somatostatin mechanism of action in, 836-841

rat islet cell membrane  
monoclonal antibodies reacting with antigens of, 226-230

rat islet cells  
 $\beta$ -adrenergic binding sites in, 172-174

antibodies and complement blockade of insulin release by, 231-234

calcium content response to glucose in, 52-54

glucose metabolism and glucokinase study, 923-928

myo-inositol concentrations and insulin content, synthesis and secretion and incorporation of  $^3\text{H}$ -thymidine into DNA, 621-625

regulation of glucose metabolism in, 911-921

and 3-isobutyl-1-methyl-xanthine priming of insulin release in, 754-756

from nicotinamide and streptozotocin-treated rats, glucose-induced insulin release from, 302-308

and trifluoperazine inhibition of glucose-stimulated insulin release, 960-966

zinc-induced inhibition of insulin secretion from, 341-344

rat islet xenografts in mice  
prolongation of survival of, 285-290

ratfish islet cells populations

differing glucagon immunoreactivity of, 192-195

somatostatin  
decrease in neonatal nesidioblastosis, 122-125

somatostatin secretion abnormalities in diabetic rats  
insulin therapy and, 865-867

transplantation in streptozotocin-diabetic rats  
glomerular lesions and, 111

reversal of increased gastric somatostatin release and, 724-726

#### **PANCREATECTOMY**

in dogs  
and transplantation of islet cells prepared by new method, 456-458

duodeno-, gastrectomy and  
and glucagon immunoreactivity and somatostatin action, 851-855

and effect of islet-activating protein in dogs, 433-434

insulin requirements after, 641-642

#### **C-PEPTIDE**

assays  
in continuous central venous insulin infusion study, 711

and insulin and glucose response to glucagon injection  
in mild and severe diabetics and normal subjects, 685-692

levels  
and exercise in normals and diabetics, 985

urinary excretion  
correlation with insulin secretion in normal subjects, 639-642

#### **PERICYTES**

degeneration in skeletal muscle capillaries of diabetics, 326-333

#### **PGI<sub>2</sub>. See Prostacyclin**

#### **pH**

during recovery phase of diabetic ketoacidosis, 311, 312

effect on insulin binding and action in cultured human fibroblasts, 402-405

#### **PHENFORMIN**

toxicity  
and reduced hydroxylation of phenformin, 644-649

#### **PHENYLALANINE**

release from skeletal muscle  
and insulin resistance in pregnancy, 549

#### **PHOSPHATIDYLINOSITOL**

breakdown in rat pancreas  
insulin and insulin secretagogues and, 396-401

#### **PHOSPHODIESTERASE**

cyclic AMP  
in adipose tissue from insulin-treated streptozotocin-diabetic rats, 372-375

#### **PHOSPHOFRUCTOKINASE**

and ketoacidosis, 346-352

#### **6-PHOSPHOFRUCTOKINASE**

assay for fructose 2,6-bisphosphate in diabetic rat liver, 1062-1064

#### **PHOSPHORYLASE**

in gastrocnemius muscle tissue  
fasting serum insulin and glucose tolerance and, 21-22, 24

in skeletal muscle of genetically obese-diabetic mice  
epinephrine and anoxia and, 214-215

#### **PHYSICS**

and study of development of diabetic atherosclerosis, \*97-103

#### **PIG. See Swine**

#### **PIMA INDIANS**

diabetic and nondiabetic  
and urinary excretion and renal clearance of specific plasma proteins, duration of diabetes and, 656-662

obese glucose-intolerant and with normal glucose tolerance  
insulin resistance in, 744

#### **PITTSBURGH**

insulin-dependent Diabetes Mellitus Registry, 279-283

#### **PITUITARY-ADRENAL AXIS**

and idiopathic postabsorptive hypoglycemia, 465, 469

#### **PLACENTA**

insulin binding studies, 196-201

membranes  
binding studies with new insulin analogues, 519-520, 521

#### **PLASMA**

acetaldehyde  
and chlorpropamide alcohol flush, 788-790

alanine and lactate  
and hyperglucagonemia in dogs, 183-184

#### **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



# SUBJECT INDEX 1981

- albumin
  - extravasation into cerebral cortex of streptozotocin-diabetic rats, 500-503
- aqueous and -vitreous barriers in streptozotocin-diabetic rats,
  - glucose transport across, 903-905
- cholesterol
  - in diabetes, \*76, \*77
- dopamine- $\beta$ -hydroxylase activity
  - in streptozotocin-diabetic rats, 416-423
- epinephrine and norepinephrine responses
  - in insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628-629, 631
- factor VIII
  - in diabetics, \*35-36
- free fatty acid levels
  - and hypersomatostatinemia of insulin deficiency, 358-360
- gastrointestinal insulinotropic hormones
  - response to oral glucose in normal and gestational-diabetic pregnancy, 504-508
- glucagon
  - hepatic glucose production and, 490
- glucose
  - and diagnosis of postprandial hypoglycemia, 996-999
  - in dietary prevention of nephropathy in diabetic mice, 107
  - and exercise in diabetics, 818-822
  - and insulin infusion pump during diabetic pregnancy, 892-895
  - in rural-urban diabetes prevalence study in Polynesians, 47-50
  - and sodium 5-methoxysalicylate-enhanced intestinal insulin absorption in rats, 1065-1066
  - in streptozotocin-diabetic rats with fetal pancreatic grafts, 10-11
- glucose, acetoacetate, beta-hydroxybutyrate, and acetone
  - in diabetic ketoacidosis before and after partial rehydration, 510-517
- glucose, insulin, free fatty acids, and triglycerides
  - in streptozotocin-diabetic rats, \*67-68
- glucose, insulin, and glucagon
  - in streptozotocin-treated rats and normal rats, 189
- glucose, insulin, glucagon, glycerol, alanine, and lactate
  - in insulinoma patients with hypoglycemia, 378
- glucose, insulin, and C-peptide response to glucagon injection in normal and diabetic subjects
  - kinetic analysis of, 685-692
- glucose concentration
  - and activation of hormonal glucose counterregulatory systems, 262-263
  - and glucose utilization and clearance in normal man, 535-537
- glucose determinations
  - in mice, 90
- glucose levels
  - and insulin therapy in type II insulin-resistant diabetics, 739-744
  - after oral glucose tolerance tests and mixed meals in hypoglycemia patients, 465-469
- immunoreactive glucagon
  - arginine stimulation of, in duodenopancreatectomized and gastrectomized human, 851-855
- immunoreactive glucagon components
  - hepatic extraction in dogs of, 767-779
- immunoreactive insulin
  - in diabetic and normal mice, 108, 110
- insulin
  - and glucose counterregulation in man, 261-264
  - response to glucose, atherosclerotic vascular disease risk and, \*58-59
- insulin and glucagon levels in dogs
  - exorphins and, 362-364
- in glycogenolysis and gluconeogenesis study, 182
- oxytocin infusion and, 112-114
- insulin and glucose
  - brief, irregular oscillations of basal concentrations in diabetics, 435-439
  - and colchicine administration, 1008-1012
- insulin levels
  - and insulin evaluation in diabetics, 650-655
- lipid and glucose levels
  - of triphenyltin fluoride-treated rabbits, 1015-1016
- lipids
  - dietary fat and cholesterol and, \*88
  - in insulin-dependent diabetics, 132-137
- lipoprotein composition
  - triphenyltin fluoride and, 1017
- lipoproteins
  - metabolism in atherosclerosis \*60-65
- norepinephrine
  - and effect of insulin and glucose infusions on sympathetic nervous system activity in normal man, 219-225
- C-peptide, glucagon free fatty acids, and 3-hydroxybutyrate
  - and exercise in diabetics and normals, 985-986
- phenformin levels
  - and phenformin toxicity study, 644-649
- proteins
  - urinary excretion and renal clearance, diabetes duration and, 656-662
- removal of very-low-density lipoproteins
  - in streptozotocin-diabetic rats, 496-499
- somatomedin C
  - in children with insulin-dependent diabetes, effect of pubertal stage and blood glucose control on, 868-871
- somatostatin
  - radioimmunoassay, 728-733
- somatostatin-like immunoreactivity
  - measurement by radioimmunoassay after affinity chromatography, 471-474
  - in study of somatostatin hormonal status in man, 883-885
- $\beta$ -thromboglobulin and platelet factor 4
  - and coronary artery disease, peripheral artery disease, and diabetes, \*33-34
- triglyceride, cholesterol and lipoproteins
  - in obese children of obese parents, 15-17
- very-low-density lipoproteins
  - and high carbohydrate diet, 530-533

## PNEUMOCOCCAL IMMUNIZATION

in adult diabetics, 119-121

## POLYMORPHONUCLEAR LEUKOCYTES

from insulin-treated diabetics  
decreased stimulation of glucose oxidation and iodination by, 256-259

## POLYNEUROPATHY

diabetes prevalence study  
rural-urban comparisons, 45-50

symptomatic in diabetics  
and electrophysiological test results compared with clinical course, 139-147

## POLYOLS

accumulation in peripheral nerves  
and lens in diabetic and galactose-fed rats, 459

## POLYPEPTIDES

pancreatic  
in infants of diabetic mothers, 271-273

## POPULATION STUDIES

of atherosclerotic vascular disease risk and plasma insulin response to glucose, \*58-59  
of hyperglycemia as risk factor for atherosclerosis, \*50-52

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- of insulin-dependent juvenile onset diabetes  
hypertension and mortality in, \*90-96  
and relationship between insulin levels  
and atherosclerosis, \*54-55
- PORTAL VEIN**  
transplantation of isolated rat islets into  
diabetic mice via, 285-290
- POTASSIUM**  
glucose and insulin infusions and  
cardiotonic effects of, 225  
Na, K-ATPase-mediated uptake  
and sucrose overfeeding in normal  
and genetically obese mice,  
975-978  
permeability in islet B-cells  
somatostatin and, 836-841  
-stimulated calcium uptake and insulin  
release  
and trifluoperazine, 961-962
- PREDNISONE**  
and insulin binding by erythrocytes and  
monocytes, 899
- PREGNANCY**  
in female rats with fetal pancreatic grafts,  
10  
and hyperinsulinemia, 504  
and skeletal muscle metabolism in rats,  
545-550
- PREGNANCY, DIABETIC**  
control during  
and prevention of congenital lumbo-  
sacral defects in rats during or-  
ganogenesis, 965-969  
gestational  
and gastrointestinal insulinotropic hor-  
mones response to oral glucose,  
504-508  
and immunocytochemical study of pan-  
creatic specimens from infants,  
271-273  
insulin infusion pump treatment in, 891-  
895
- PROCOLLAGEN**  
type 1  
in arterial wall, growth hormone and,  
\*16
- PROGESTERONE**  
and expression of mutations at diabetic  
locus in male mice, 1036-  
1039  
and skeletal muscle metabolism in rats,  
548-550
- PROINSULIN**  
incomplete conversion to insulin, 148
- secretion  
from isolated rat islets, age and, 77-  
82
- PROLACTIN**  
and rat islet tumor growth in serum-free  
medium, 1022-1027
- PROPERDIN FACTOR B ALLELES**  
and lymphocytotoxic antibodies in juve-  
nile-onset diabetes, 27, 28
- PROPRANOLOL**  
epinephrine, glucose, and insulin infu-  
sions for measurement of insulin  
resistance in mildly diabetic or  
hyperlipidemic men  
cardiac arrhythmias during, 618-620
- PROSTACYCLIN**  
and insulin secretion and cyclic AMP  
content of rat isolated islets,  
824-827  
production  
by endothelial cells from large and  
small vessels, \*26  
by isolated rat adipocytes, 163-166
- PROSTAGLANDIN E**  
release  
and colchicine inhibition of insulin  
secretion, 1008-1012  
synthesis in neonatal rat pancreas  
insulin secretion and, 551-556
- PROSTAGLANDIN ENDOPEROXIDES**  
synthesis by platelets, \*47
- PROSTAGLANDINS**  
in isolated rat adipocytes, 164
- PROTEASE INHIBITORS**  
in diabetes, \*36
- PROTEIN**  
and coagulation \*34-35  
/DNA ratio in kidneys of diabetic rats  
kidney cell size calculations and,  
484, 485  
dietary  
peptides with opioid-like activity in  
peptic digests of, 362-364  
glycosylated in diabetes, 616  
islet-activating, *see* Islet-activating pro-  
tein  
myelin  
proteolysis in streptozotocin-diabetic  
rats, 292-294  
rapid axonal transport in diabetic rats,  
797-802  
urinary excretion and renal clearance  
diabetes duration and, 656-662
- PROTEIN ACTIVATOR**  
of cyclic AMP phosphodiesterase  
in adipose tissue of streptozotocin-di-  
abetic insulin-treated rats, 372-  
375
- PROTEIN A-GOLD TECHNIQUE**  
and demonstration of glucagon in  
human fetal stomach, 879-882
- PROTEINURIA**  
in juvenile-onset, insulin-dependent dia-  
betics, 178
- PROTEOGLYCANS**  
of cartilage and bone  
biosynthesis abnormalities in strepto-  
zotocin-diabetic rats, 670-677
- PROTEOLYSIS**  
of myelin proteins  
in streptozotocin-diabetic and normal  
rats, 292-294
- PROTEOSE PEPTONE**  
and rat islet tumor growth in serum-free  
medium, 1022-1027
- PROTHROMBIN**  
in diabetes, \*35
- PUBERTY**  
and plasma somatomedin C in insulin-  
dependent diabetic children,  
868-871
- PYRUVATE DEHYDROGENASE**  
in skeletal muscle of genetically obese-  
diabetic mice  
insulin and, 216

**Q**

- QUININE**  
and electrophysiologic activity of soma-  
tostatin in islet B-cells, 837-841

**R**

- RABBITS**  
alloxan diabetic  
and energy metabolism in peripheral  
nerve axons and Schwann cells,  
967-974  
aorta  
comparison of two types of reaction to  
arterial wall injury in, \*11-12  
mechanical injury and formation of  
atherosclerotic lesions, \*8-9  
and selective endothelial injury, \*10-  
11  
aorta myomedial cells growth

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110
			December, 983-1113

# SUBJECT INDEX 1981

as model of diabetic macroangiopathy, \*14-16  
cholesterol-fed, alloxan-diabetic insulin deficiency and atherosclerosis incidence in, \*55  
endothelial injury and artery wall injury in, \*2-3  
triphenyltin fluoride-induced hypertriglyceridemia in, 1013-1020

## RACE

and atherosclerosis incidence in Japanese diabetics, \*1  
and insulin-dependent diabetes in Pittsburgh Registry, 280, 281, 283  
and urinary excretion and renal clearance of plasma proteins  
in Pima Indians and Caucasians, 656-662

## RADIOIMMUNOASSAYS

for human plasma somatostatin, 728-733  
for <sup>125</sup>I-insulin, 2  
for lymphocyte hybrid cell antibodies, 227  
of pancreatic tissue from neonates with nesidioblastosis, 123, 124-125  
of somatostatin-like immunoreactivity in human peripheral plasma  
affinity chromatography prior to, 471-474

## RAT

adipocytes  
insulin-induced receptor loss and internalization in, 746-752  
adipocytes and hepatocytes  
<sup>125</sup>I-insulin binding in, 4-5  
adipocytes and liver insulin receptors  
insulin binding studies, 196-201  
alloxan diabetic  
and hepatic fructose 2,6-bisphosphate levels, 1062-1064  
alloxan diabetic and fasted  
coagulation studies in, \*36-37  
aorta  
6-oxo-prostaglandin F<sub>1α</sub> production, diabetes, insulin, and caloric deprivation and, 935-938  
arterial smooth muscle cells  
insulin effects on lipid metabolism of, \*56-57  
cultured pancreatic islets  
myo-inositol concentration and glucose-induced insulin secretion and <sup>3</sup>H-thymidine incorporation into DNA, 621-625  
diabetic  
intestinal glucose uptake in, 247-255  
diabetic and galactose-fed  
peripheral nerves and lens sorbitol and galactitol accumulation in, 459

fed and starved  
and regulation of ornithine decarboxylase in skeletal muscle, 668-683  
fetal and neonatal  
glucose-induced insulin secretion in, 56-62  
fetal pancreas  
transplantation into adult diabetic rats, 9-12  
gastrointestinal insulin absorption and sodium 5-methoxysalicylate, 1065-1066  
genetically obese-hyperglycemic new Wistar fatty strain, 1045-1049  
glomerular basement membrane  
nonenzymatic glycosylation of, 367-370  
glucose- and arginine-induced insulin release and glucose tolerance in  
vincristine and, 539-544  
inhibition of superoxide dismutase by diabetogenic drugs in, 235-240  
islet allograft transplantation in  
cellular stimuli for rejection of, 242-246  
donor strain blood transfusions and ALS therapy and, 947-950  
islet B-cells  
somatostatin mechanism of action in, 836-841  
islet cell membrane antigens  
monoclonal antibodies reacting with, 226-230  
islet tumor cells  
hormones and factors stimulating growth of, 1022-1027  
islets  
and trifluoperazine inhibition of glucose-stimulated insulin release, 960-966  
transplantation into mice, prolongation of survival of, 285-290  
zinc-induced inhibition of insulin secretion from, 341-344  
isolated adipocytes  
prostacyclin production, 163-166  
isolated islets  
effect of age on proinsulin and insulin secretory patterns in, 77-82  
3-isobutyl-1-methyl-xanthine priming effect on insulin release, in, 754-756  
prostacyclin and 6-keto-prostaglandin F<sub>1α</sub> effects on insulin secretion and cyclic AMP content in, 824-827  
isolated, perfused pancreas  
effect of muscimol on glucose-stimulated somatostatin and insulin release from 168-170  
glucose and cyclic AMP stimulation of somatostatin and insulin secretion in 40-44

neonatal pancreas  
and prostaglandin E synthesis and insulin secretion study in, 551-556  
neonatal pancreatic islets  
streptozotocin and, 64-69  
neonatal streptozotocin diabetes  
as model for non-insulin-dependent diabetes, islet secretion studies in, 590-594  
newborn pancreas monolayer cultures  
and effects of veratridine and calcium on glucagon and insulin secretion from, 446-449  
nicotinamide- and streptozotocin-treated islet tissues and adenomas from, glucose and insulin release studies in, 302-308  
pancreas  
effects of insulin and insulin secretagogues on calcium-dependent phosphatidylinositol breakdown and amylase secretion in, 396-401  
pancreatic islets  
calcium content response to glucose in, 52-54  
exposure to islet-cell-specific antibodies and complement, insulin release and, 231-234  
glucose metabolism, glucokinase and, 923-928  
preponderance of β-adrenergic binding sites in, 172-174  
regulation of glucose metabolism in, 911-921  
postnatal  
pancreatic islet development in, 813-817  
retina and erythrocytes superoxide dismutase  
and diabetogenic drugs, 235  
skeletal muscle metabolism  
effects of pregnancy and sex steroids on, 545-550  
spontaneous insulin-dependent diabetes  
and lymphocytic thyroiditis, 1058-1060  
spontaneously diabetic Wistar "BB" T-cell lymphocytopenia in, 887-889  
spontaneously obese, insulin resistant, and hyperinsulinemic  
streptozotocin and hypertriglyceridemia in, \*70-71  
streptozotocin-diabetic  
arterial wall lipid metabolism in, \*55  
bioartificial pancreas in, 296-301  
and cartilage and bone proteoglycans biosynthesis abnormalities in, 670-677  
cerebral edema following fluid and insulin therapy in, 762-766  
in cholesterol metabolism studies, \*79-81  
and cyclic AMP phosphodiesterase

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

and protein activator in adipose tissue from, 372-375  
gastric somatostatin concentration and secretion in, 188-191  
glucose transport across ocular barriers of, 903-905  
hypertriglyceridemia in, \*66, \*67-68, \*69, \*70-71, \*72-74  
and increase in arterial myomedial cells, \*15-16  
iodotyrosine metabolism in, 694-698  
islet cell transplantation and kidney hypertrophy and glomerular basement membrane accumulation in, 481-485  
pancreas transplantation effects on gastric somatostatin release in, 724-726  
pancreatic somatostatin secretion abnormalities and insulin treatment in, 865-867  
plasma dopamine- $\beta$ -hydroxylase activity in, 416-423  
and plasma protein extravascular escape into cerebral cortex, 500-503  
and plasma removal of very-low-density lipoproteins, 496-499  
platelet aggregation and coagulation in pathogenesis of retinopathy in, 601-606  
proteolysis of myelin proteins in, 292-294  
retrograde transport of proteins in sciatic nerves of, 797-802  
sugar transport in isolated small intestine from, 568-574  
streptozotocin-diabetic pregnancy in and prevention of congenital lumbosacral defects in offspring, 965-969  
vitamin D-deficient and effect of 1,25 dihydroxy-vitamin D<sub>3</sub> on insulin secretion in, 382-385

#### RATFISH

pancreatic islets  
differing glucagon immunoreactivity of islet cells of, 192-195

#### RECOMBINANT DNA METHODOLOGY

and insulin synthesis, 265-266

#### RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

in diabetics with hyperkalemia, 335-339

#### RESPIRATION

exchange measurement and insulin clamp studies of glucose disposal, 100

#### RETINOPATHY, DIABETIC

and deterioration and closure of preexisting vessels \*24  
in long-term study of juvenile-onset insulin-dependent diabetics, 177-178  
platelet activation and plasma thromboxane B<sub>2</sub> in, \*42  
and platelet release factors, \*34  
in streptozotocin-diabetic rats  
platelet aggregation and coagulation in pathogenesis of, 601-606

#### RIBOSE

and somatostatin, insulin, and glucagon release, 207-209

#### RISK FACTORS FOR ATHEROSCLEROSIS

effects on platelets and vascular endothelium, \*39-42  
and endothelial and smooth muscle cells in diabetics, \*41-42  
and homocystinuria, \*40  
and hyperlipidemia, \*40-41  
and hypoxia, \*41  
and high-density lipoproteins in diabetics, \*86  
hyperglycemia, \*49-53  
and hypertension in juvenile-onset insulin-dependent diabetics, \*90-96  
plasma cholesterol levels and, \*76, \*78  
and role of insulin in atherosclerosis, \*54, \*55

#### RNA

antibodies to  
in insulin-dependent diabetics and unaffected relatives, 873-874  
kidney content  
in streptozotocin-diabetic rats, 484, 485

#### S

#### SCATCHARD PLOTS

in insulin binding studies, 199, 200  
of <sup>125</sup>I-insulin binding to sheep erythrocytes, 412-414  
of somatostatin and glucagon binding data from human mononuclear leukocytes, 128, 130

#### SCIATIC NERVE

rapid axonal transfer of proteins in streptozotocin-diabetic rats, 797-802

#### SEMICARBAZIDE

and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701

#### SERUM

Alrestatin levels  
in clinical trial of Alrestatin in diabetic neuropathy, 460, 462, 463  
antiglucagon and antiglucagonin and human fetal stomach glucagon, 879-882  
anti-insulin  
binding studies with new insulin analogues, 519, 520-521  
antilymphocyte  
and blood donor-specific pretreatment, pancreatic islet allograft survival in rats and, 947-950  
in mice given multiple low doses of streptozotocin, 427-428  
antiplatelet  
and prevention of atherosclerosis in mechanically injured arteries, \*9  
cholesterol, high density lipoproteins, and triglycerides  
and hypertension as risk factor in insulin-dependent, juvenile-onset diabetics, \*94, \*96  
diabetic  
and PAS-positive fibronectin and collagen in arterial wall, \*16  
from diabetic and nondiabetic rats  
and ornithine decarboxylase regulation in rat skeletal muscle, 681-682, 683  
from diabetic patients, soluble immune complexes from  
platelet aggregation and ATP release after incubation with 575-578  
from diabetic patients with complement-fixing islet-cell antibodies  
and insulin release in vitro from isolated mouse islets incubated with, 1051-1056  
electrolytes and organic acids  
and hyperchloremic acidosis during recovery phase of diabetic ketoacidosis, 310-313  
fibrinogen  
in diabetics, atherosclerosis and, \*3  
glucose  
and prevention of lumbar and sacral malformations in offspring of streptozotocin-diabetic rats, 965-969  
glucose responses and free insulin concentrations  
and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628, 631  
glycosidase activity  
in diabetics, 115-117  
insulin  
and adipocyte size, 19  
and skeletal muscle morphology and enzyme activities, 19-25  
and tumor development in nicotinamide- and streptozotocin-treated rats, 304

#### DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



lymphocytotoxic antibodies  
in sera from insulin-dependent juvenile-onset diabetics, 26-29  
nitrogenous compounds and electrolytes  
during rehydration in diabetic ketoacidosis, 514-515  
from patients with familial hypercholesterolemia, familial hypertriglyceridemia, and combined hyperlipidemia  
and endothelial cells, \*40-41  
potassium  
and hyperkalemia in diabetics, renin-angiotensin-aldosterone system and, 335-339  
unmeasured anion gap in metabolic acidosis, 781-783, 783-785

## SEX

and cardiovascular disease mortality in normoglycemic, borderline diabetic, and diabetic men and women, \*50-52  
and coronary artery disease in diabetics, \*14  
and expression of spontaneous diabetes in mice, 1029-1030, 1035-1043  
and expression of mutations at diabetes locus in mice  
male lethal syndrome and, 1035-1043  
and hyperinsulinemia and atherosclerosis, \*5  
of hypoglycemia patients in postabsorptive hypoglycemia study, 466  
of insulin-dependent diabetics in Pittsburgh Registry, 280, 281, 283  
of insulin-resistant non-insulin dependent diabetics, 991  
and risk of occlusive vascular disease in diabetics, \*2  
in rural-urban diabetes prevalence study in Polynesians, 47, 48, 49  
and serum glycosidase activity in diabetics and normals, 116

## SHEEP

erythrocyte insulin receptors  
disappearance during maturation, 411-414

## SKIN

albumin deposition in dermal capillary basement membrane  
in insulin-dependent diabetics, 275-278  
cultured human fibroblasts  
effect of pH and 3-hydroxybutyrate on insulin binding and action in, 402-405  
from patients with maturity-onset diabetes of the young, insulin binding and action in, 940-945

cultured human fibroblasts from diabetics and nondiabetics  
insulin binding, internalization, and insulin receptor regulation in, 596-600  
insulin and glucose metabolism study of, 562-566  
photosensitive rash  
in aldose reductase inhibitor trial in diabetic neuropathy patients, 462, 463

## SMOKING

and endothelial damage, \*2  
and hypertension as risk factor for atherosclerosis  
insulin-dependent juvenile-onset diabetics, \*94, \*96  
and hypoxia and atherosclerosis  
endothelial and smooth muscle cell function in low oxygen environment and, \*41  
serum insulin, glucose tolerance and muscle enzyme activity, 23

## SOCIOECONOMIC FACTORS

in rural-urban diabetes prevalence study in Polynesian populations, 46

## SODIUM

and insulin and glucagon secretion  
calcium and, 446-449

## SODIUM 5-METHOXY-SALICYLATE

and intestinal insulin absorption in rats, 1065-1066

## SODIUM-POTASSIUM PUMP

-mediated potassium uptake in obese and normal mice  
sucrose overfeeding and, 975-978

## SODIUM SALICYLATE

and inhibition of prostaglandin E synthesis in neonatal rat pancreatic cells  
and insulin secretion, 551-556

## SOMATOMEDIN-C

binding to cultured lymphocytes  
inhibition by naturally occurring antireceptor antibodies, 979-981  
in plasma of insulin-dependent diabetic children  
effects of pubertal stage and recent blood glucose control on, 868-871  
and rat islet tumor cell growth in serum-free medium, 1025

## SOMATOSTATIN

antidiabetic action of  
in totally duodeno-pancreatectomized and gastrectomized humans, 851-855  
-binding mononuclear leukocytes in human blood, 127-131  
and flow rate and triglyceride levels of thoracic duct lymph  
in normal and vagotomized dogs, 440-444  
gastric concentration and secretion of in streptozotocin-diabetic rats, 188-191  
gastric content and release in streptozotocin-diabetic rats  
pancreas transplantation and, 724-726  
and glucagon deficiency in dogs  
liver glucose production and, 490-494  
glucose-stimulated release from isolated perfused rat pancreas  
muscimol and, 168-170  
hormonal status in man, 883-885  
-like immunoreactivity in human peripheral plasma  
radioimmunoassay following affinity chromatography and measurement of, 471-474  
mechanism of action  
in rat islet B-cells, 836-841  
pancreatic decrease in neonatal nesidioblastosis, 122-125  
in pancreatic specimens from infants of diabetic mothers, 271-273  
radioimmunoassay in human plasma, 728-733  
release  
glucose-mediated, 203-209  
responses to theophylline, high glucose, and arginine  
by islets from new animal model for non-insulin-dependent diabetes, 593, 594  
secretion  
from isolated, perfused rat pancreas, glucose and cyclic AMP and, 40-44  
secretion abnormalities in diabetic rats  
insulin therapy and, 865-867  
splanchnic release  
and insulin, 735-738  
and plasma free fatty acids, 358-360  
-suppression of insulin secretion  
portal vein hormone measurements and, 664-668

## SORBITOL

accumulation in peripheral nerves and lens of diabetic rats, 459  
intracellular accumulation of  
endothelial injury in diabetics and, \*2

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113



**SPINE**

- lumbar and sacral malformations in offspring of streptozotocin-diabetic rats
- and diabetic control, 965-969

**SPLANCHNIC NERVE**

- glucose production
- insulin and, 1000-1006
- protein- and acid-induced somatostatin release in dogs
- insulin and, 735-738

**SPLEEN**

- cells
- and rejection of islet allografts, 242-246, 289-290

**STARVATION**

- and ornithine decarboxylase regulation in rat skeletal muscle, 678-683
- and rat hepatic fructose 2,6-bisphosphate levels, 1062-1064
- and wound healing in mice, 407-410

**STERIODS.** *See also* Progesterone; Testosterone

- and skeletal muscle metabolism in rats, 548-550

**STEROL**

- suppression by triglyceride-rich lipoproteins in contact-inhibited endothelial cells, \*21-22

**STEROL BALANCE TECHNIQUES**

- in cholesterol metabolism studies in diabetes, \*76-81

**STOMACH**

- gastric somatostatin concentration and secretion
- in streptozotocin-diabetic rats, 188-191
- of human fetuses
- glucagon in, 879-882
- of streptozotocin-diabetic rats
- reversal of increased gastric somatostatin by pancreas transplantation, 724-726

**STREPTOZOTOCIN**

- diabetogenic effects in mice
- age and, 718-722
- inhibition of islet superoxide, 235-240
- multiple low doses in mice
- pancreas islet mass and B-cell function loss preceding hyperglycemia in, 424-429
- neonatal rat islets responses to, 64-69
- and nicotinamide-treated rats
- insulin release from islet tissues and adenomas of, 302-308

**STREPTOZOTOCIN DIABETES**

- in mice
- effects of exogenous superoxide dismutase on, 634-638
- and rat islet xenograft survival prolongation, 285-290
- and subcutaneous, isogeneic transplants of duct-ligated pancreas, glucose tolerance studies in, 857-863
- in neonatal rats
- and islet secretion studies as model for non-insulin-dependent diabetes, 590-594
- in rats
- and adipose tissue cyclic AMP phosphodiesterase and protein activator, 372-375
- anterograde and retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in, 797-802
- and bioartificial pancreas, 296-301
- and cartilage and bone proteoglycans biosynthesis abnormalities, 670-677
- and cerebral edema following fluid and insulin therapy, 762-766
- in rats
- and cholesterol metabolism studies, \*78-81
- and diabetic hypertriglyceridemia, \*66, \*67-68, \*69, \*70-71, \*72-74
- and gastric somatostatin concentration and secretion, 188-191
- and gastric somatostatin release, pancreas transplantation and, 724-726
- and glomerular lesions, 111
- and glucose transport across ocular barriers, 903-905
- and increase in arterial myomedial cells, \*15-16
- and increased plasma dopamine- $\beta$ -hydroxylase activity, 416-423
- and intestinal glucose uptake, 247-255
- and iodothyronine metabolism, 694-699
- and kidney hypertrophy and glomerular basement membrane accumulation after islet cell transplantation, 481-485
- and myelin protein proteolysis, 292-294
- and 6-oxo-prostaglandin production by aorta, 935-938
- pancreatic somatostatin secretion abnormalities and insulin treatment in, 865-867
- plasma proteins extravascular escape into cerebral cortex of, 500-503
- and plasma removal of very-low-density lipoproteins, 496-499
- and platelet aggregation and coagulation in pathogenesis of retinopathy, 601-606
- and prevention of congenital lumbosacral defects in offspring, 965-969
- and sugar transport in isolated small intestine from, 568-574
- and transplantation of fetal pancreas, 9-12
- in Syrian hamsters
- and microvascular alterations, 93-100

**STROKE**

- and atherosclerosis, \*39

**SUCCINATE DEHYDROGENASE**

- in gastrocnemius muscle tissue
- fasting serum insulin and glucose tolerance and, 21-22, 24

**SUCROSE**

- overfeeding
- and Na, K-ATPase mediated potassium uptake in normal and obese mice, 975-978

**SUGARS**

- and pancreas D-cell recognition of D-glucose, 203-209
- transport
- in isolated small intestine of streptozotocin-diabetic rats, 568-574

**SULFONYLUREAS**

- and blood platelet aggregation in diabetics, 488

**SUPEROXIDE DISMUTASE**

- inhibition by diabetogenic drugs, 235-240
- in mice with multiple low doses of streptozotocin, 634-638

**SURGERY.** *See also* Pancreatectomy

- duodeno-pancreatectomy and gastrectomy in humans
- glucagon immunoreactivity and anti-diabetic action of somatostatin in, 851-855
- for implantation of peritoneal insulin infusion device, 1073
- vagotomy in dogs and effect of somatostatin on thoracic duct lymph flow rate and triglyceride levels, 440-444

**SWINE**

- miniature
- cholesterol-fed, anterior coronary arteries from, \*60, \*61

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

pancreas  
pseudo-islets formed from single cell  
preparations of, 580-583  
Von Willebrands disease and  
resistance to atherosclerosis in, \*3

# **SYRIAN HAMSTERS**

streptozotocin-induced diabetes in  
and microvascular alterations, 93-  
100

## **T**

### **TEMPERATURE**

of donor islets  
and prolongation of islet xenograft  
survival in mice, 285-290  
hyperglycemia and microangiopathy in  
cold-adapted eels, 317-325  
and insulin-induced receptor loss  
and internalization of insulin receptor  
in rat adipocytes, 747-752  
rectal  
in insulin-induced hypoglycemia in  
diabetics with and without au-  
tonomic neuropathy, 630, 631,  
632

### **TESTOSTERONE**

and expression of mutations at diabetic  
locus in male mice, 1036-  
1039

### **TETRODOTOXIN**

and veratridine-induced glucagon and  
insulin secretion in rat pancreas,  
447-448, 449

### **THEOPHYLLINE**

and glucose- and arginine-induced in-  
sulin secretion  
by islets from new animal model for  
non-insulin-dependent diabetes,  
592-593, 594

### **THIAZIDES**

and hypertension therapy  
carbohydrate tolerance and, \*2

### **THIOL**

and iodotyrosine metabolism in diabetic  
rats, 694-698

### **THORACIC DUCT**

lymph flow rate and triglyceride levels  
and somatostatin in normal and vago-  
tomized dogs, 440-444

### **THROMBIN-ANTITHROMBIN AXIS**

and coagulation in diabetics, \*37

### **THROMBOCYTOPENIA**

induced in rabbits  
and antiplatelet serum, \*9

### **$\beta$ -THROMBOGLOBULIN**

in plasma of coronary artery disease,  
peripheral artery disease and  
diabetes patients, \*33-34  
radioimmunoassay  
in platelet activation study in diabet-  
ics, \*42

### **THROMBOSIS**

coronary artery  
in acute myocardial infarction, \*39

### **THROMBOXANE A<sub>2</sub>**

and atherogenesis, \*3  
and coronary spasm, \*39  
in isolated rat adipocytes, 164  
synthesis  
and platelet arachidonic acid metab-  
olism in diabetics, \*44-47

### **<sup>3</sup>H-THYMIDINE**

incorporation into DNA of rat pancreatic  
islets  
myo-inositol inhibition of, 622, 623-  
624

### **THYROID GLANDS**

and lymphocytic thyroiditis in insulin-  
dependent diabetic rats, 1053-  
1060

### **THYROIDITIS**

and diabetes, 1058-1060  
lymphocytic  
in diabetic rat, 1058-1060

### **TISSUES**

capillaries of eels  
and cold adaptation, 317-325  
differential inhibition of superoxide dis-  
mutase by diabetogenic drugs  
in, 235-240  
gastrocnemius muscle  
enzyme activities in relation to fasting  
serum insulin and glucose toler-  
ance, 19-25  
insulin receptors  
differences in insulin binding charac-  
teristics, 196-201  
isolated rat adipocytes  
prostacyclin production, 163-166  
pancreatic  
and decrease of somatostatin in neo-  
natal nesidioblastosis, 122-125  
from infants of diabetic mothers, his-  
tological studies of, 271-273  
from skeletal muscle capillaries of dia-  
betics

pericyte degeneration and basement  
membrane thickening, in, 326-  
333

### **TRANSFERRIN**

/immunoglobulin G clearance ratios  
as index for protein excretion, 658,  
659, 661, 662  
and rat islet tumor growth in serum-free  
medium, 1022-1027

### **TRANSPLANTATION**

of fetal mouse pancreas into streptozo-  
tocin-diabetic mice  
in study of culture conditions and in-  
sulin and glucagon secretion,  
806-811  
of islet allografts  
and rejection caused by contamina-  
tion by passenger leucocytes,  
242-246  
of islet allografts in rats  
donor strain blood transfusion and an-  
tilymphocyte serum and, 947-  
950  
islet cell in streptozotocin-diabetic rats  
and kidney hypertrophy and glomeru-  
lar basement membrane accu-  
mulation, 481-485  
neonatal pig pseudo-islets as xenograft  
source for, 580  
pancreas  
and glomerular lesions in streptozo-  
tocin-diabetic rats, 111  
in streptozotocin-diabetic rats, rever-  
sal of increased gastric soma-  
tostatin release and, 724-726  
and prolongation of rat to mouse islet  
xenograft survival, 285-290  
of rat fetal pancreas into adult strepto-  
zotocin-diabetic rats, 9-12  
subcutaneous, isogenic duct-ligated pan-  
creas in diabetic mice  
glucose tolerance studies in, 857-863

### **TRIFLUOPERAZINE**

and inhibition of insulin release, 960-  
966

### **TRIGLYCERIDE**

estimates in continuous central venous  
insulin infusion study, 711  
in plasma of obese children of obese  
parents, 15-17  
in thoracic duct lymph in normal and  
vagotomized dogs  
somatostatin and, 440-444

### **TRIIODOTHYRONINE**

and rat islet tumor growth in serum-free  
medium, 1022-1027

## **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

**TRIPHENYLITIN FLUORIDE**

and hypertriglyceridemia in rabbits,  
1013-1020

**TRYPSIN**

and proteolysis in peripheral nerve  
myelin  
in streptozotocin-diabetic and normal  
rats, 292-294

**TUMORS**

adenomas induced by nicotinamide and  
streptozotocin in rats  
insulin release from, 302-308  
insulinomas  
and insulin binding by erythrocytes  
and monocytes, 896-901  
and insulin suppression of hepatic  
glucose production and hypo-  
glycemia in, 377-380  
rat islet  
hormones and factors stimulating  
growth of, 1022-1027

**TYROSINE A14 [<sup>125</sup>I]MONOIODINSU-  
LIN. See <sup>125</sup>I-Insulin**

**U**

**URIC ACID**

clearance  
and aldose reductase inhibition in  
diabetic neuropathy, 460

**URINE**

albumin excretion in response to exer-  
cise  
continuous subcutaneous insulin infu-  
sion in diabetic men and, 818-  
822  
electrolytes, organic acids, and net acid  
during recovery phase of diabetic ke-  
toacidosis, 310-313  
excretion of nitrogenous compounds  
and rehydration during diabetic ke-  
toacidosis, 510-517  
excretion of specific plasma proteins  
and diabetes duration, 656-662  
C-peptide excretion  
correlation with insulin secretion rates  
in normal subjects, 639-642  
samples  
in continuous central venous insulin  
infusion study, 711  
tests  
and aldose reductase inhibition in di-  
abetic neuropathy, 460

volume and glucose excretion  
in streptozotocin-diabetic rats with  
fetal pancreatic grafts, 10

**V**

**VACOR**

inhibition of islet superoxide dismutase,  
235-240

**VAGOTOMY**

in dogs  
and effect of somatostatin on thoracic  
duct lymph flow rate and triglyc-  
eride levels, 440-444

**VASCULAR DISEASE**

and decreased platelet survival in dia-  
betics, \*33-34  
and juvenile-onset diabetics, 175-178  
peripheral  
in diabetics, \*49-50  
and prostaglandin endoperoxides syn-  
thesis, \*47

**VASCULAR SYSTEM**

cerebral and mesenteric vessels  
in genetically diabetic mice platelet  
aggregation studies in, 89-92  
microvascular alterations in streptozo-  
toxin-diabetic Syrian hamsters, 93  
-100

**VEINS**

hepatic and femoral  
catheterization techniques, and glu-  
cose disposal measurements,  
1000-1006

**VERATRIDINE**

and glucagon and insulin secretion  
extracellular and intracellular calcium  
and, 446-449

**VINCRISTINE**

and glucose- and arginine-induced in-  
sulin release and glucose toler-  
ance in rats  
mechanism of, 539-544

**VIRUSES**

Coxsackie B4  
and HLA antigen studies in juvenile  
diabetics and controls 584-589  
encephalomyocarditis-induced diabetes  
in mice

and effects of genetic obesity, 451-  
454

herpesvirus-induced  
atherosclerosis in chickens, \*29-31

**VITAMINS**

D deficiency in rats  
and effects of 1,25 dihydroxyvitamin  
D<sub>3</sub> on insulin secretion, 382-385

**VON WILLEBRAND'S DISEASE**

and resistance to atherosclerosis  
in pigs, \*3

**W**

**WATER**

brain content  
and plasma protein extravasation into  
cerebral cortex of diabetic rats,  
502  
regional localization of cerebral  
edema following fluid and insu-  
lin therapy in diabetic rats, 762-  
766  
intake in diabetic and normal mice, 107  
unstirred intestinal layer in estimates of  
glucose kinetics, 247-255

**WEIBEL-PALADE BODIES**

in endothelial cells of large and small  
vessels, \*25-26

**WEIGHT. See Body weight**

**WHEAT GERM AGGLUTININ**

-induced insulin binding  
tissue differences in, 196-201

**WOUND HEALING**

as model of atherosclerosis, \*39-42  
in normal mice  
effects of antisera to insulin, 2-deoxy-  
glucose-induced hyperglyce-  
mia, and starvation on, 407-410

**Z**

**ZINC**

-induced inhibition of insulin secretion  
from isolated rat islets of Lan-  
gerhans, 341-344

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

# Author Index

## A

Abe, Hiromi, 188-191  
 Abe, Ryuzo, 14-18  
 Abraham, M., 664-669  
 Ainuu, J., 45-51  
 Albers, John J., 132-138  
 Alberti, K.G.M.M., 650-655, 951-954  
 Albisser, A. Michael, 710-717  
 Almer, Lars-Olof, 788-791  
 Altszuler, Norman, 112-114, 172-174, 903-906  
 Anderson, Gunnar H., Jr., 335-340  
 Anderson, Richard W., 996-999  
 Ardila, Enrique, 101-105  
 Aronoff, Stephen L., 656-663  
 Arquilla, Edward R., 407-410  
 Asbury, Arthur K., 139-147  
 Assan, Roger, 296-301, 677, 1051-1057  
 Avezzano, Eric S., 700-701  
 Axelrod, Lloyd, 163-167

## B

Baenziger, J., 875-878  
 Banerji, Mary Ann, 310-313  
 Barbosa, Jose, 873-874  
 Bar-on, Hanoch, 496-499  
 Baker, Lester, 965-969  
 Baldwin, David, Jr., 979-982  
 Bassett, David R., 618-620  
 Bates, Susan E., 891-895  
 Battistelli, F., 175-179  
 Bauer, G.E., 302-309  
 Bauman, William A., 265-266  
 Bear, Robert A., 781-787  
 Bell, Graeme, 267-270  
 Belmonte, M.M., 584-589  
 Bendayan, Moise, 317-325  
 Bennett, Peter H., 402-406, 562-567, 656-663  
 Bergström, Bengt, 788-791  
 Berhanu, Paulos, 523-529  
 Berman, Edwin L., 132-138  
 Berner, Donna K., 911-922, 923-928  
 Besse, J., 175-179  
 Best, James D., 847-850  
 Bhatena, Sam J., 127-131  
 Bianchi, Enrica, 685-693  
 Billaud, L., 175-179  
 Bilous, Rudolf W., 818-823  
 Bishop, A.E., 122-126  
 Blethen, Sandra L., 868-872  
 Blix, P., 664-669  
 Bloom, S.R., 122-126, 951-954  
 Blumenthal, Stanley A., 335-340

Bodansky, H.J., 907-910  
 Boitard, Chr., 1051-1057  
 Bolli, Geremia, 607-612  
 Bonen, A., 702-704  
 Bonner-Weir, S., 64-69, 590-595  
 Bonnevie-Nielsen, Vagn, 424-429  
 Bosio, E., 644-649  
 Braunstein, Seth N., 139-147  
 Braverman, Lewis E., 1058-1061  
 Bressler, Rubin, 106-111  
 Brimjo, Stephen, 797-803  
 Bringer, Jacques, 83-85, 851-856  
 Britt, L.D., 580-583  
 Brossa, Claudio, 685-693  
 Brown, David M., 843-846  
 Brown, Josiah, 9-13  
 Brown, Judith A., 267-270  
 Brown, Mark, J., 139-147  
 Brown, Thomas J., 773-780  
 Brunetti, Paolo, 607-612  
 Bruni, Bruno, 685-693  
 Bryant, M.G., 122-126  
 Bunker, Donna, 465-470  
 Bunn, H. Franklin, 613-617  
 Burch, Pamela Trueheart, 911-922, 923-928  
 Burnett, M., 435-439  
 Burr, Ian M., 857-864  
 Buse, Maria G., 235-241

## C

Carroll, Hugh J., 310-313  
 Cartechini, Maria G., 607-612  
 Caruso, G., 804-812  
 Caruso, Joanne, 314-316  
 Cerciello, Teresa, 1008-1012  
 Chan, Timothy M., 211-218  
 Chang, Albert, 393-395  
 Charles, M. Arthur, 465-470  
 Chavers, Blanche, 275-278  
 Chen, Yii-der, I., 496-499  
 Cherksey, Bruce, 172-174  
 Cherrington, Alan D., 180-187, 490-495  
 Cherry, Marianna, 30-39  
 Ches, P. Garin, 122-126  
 Cheung, Marian C., 132-138  
 Chiba, Tsutomu, 188-191, 724-727  
 Chick, William L., 226-230, 1022-1028  
 Chihara, Kazuo, 188-191, 724-727  
 Christensen, N.J., 626-633  
 Ciborowski, C. James, 367-371  
 Ciconali, M., 644-649  
 Clark, Samuel A., 382-386  
 Claus, Thomas H., 1062-1064  
 Clements, Rex S., 621-625

Clore, E.T., 590-595  
 Coggins, Julian T., 465-470  
 Cohen, Howard L., 947-950  
 Cohen, Margo P., 367-371  
 Coleman, Douglas L., 1029-1034  
 Colle, E., 584-589  
 Collier, S., 804-812  
 Colwell, J., 575-579  
 Compagnucci, Pietry, 607-612  
 Conover, Cheryl A., 678-684  
 Cook, Daniel L., 558-561  
 Coulston, G.L., 1068-1071  
 Court, J., 26-29  
 Coustan, Donald R., 891-895  
 Craig, James W., 402-406  
 Craighead, J.E., 451-454  
 Crepeau, M.P., 584-589  
 Crill, Wayne E., 558-561  
 Crossley, J.R., 26-29  
 Crouch, Rosalie K., 235-241  
 Crump, T., 887-889  
 Cryer, Philip E., 261-264  
 Csáky, T.Z., 568-574  
 Cudworth, A.G., 907-910

## D

D'Alberto, Micaela, 685-693  
 Dandona, P., 1068-1071  
 D'Andrea, B.J., 451-454  
 Davie, Joseph M., 242-246, 285-291  
 DeBoer, W., 45-51  
 Debray-Sachs, M., 1051-1057  
 De Feo, Pierpaolo, 607-612  
 DeFronzo, R.A., 1000-1007  
 Dehaye, J.P., 211-218  
 Delage, Anne, 101-105  
 DeLuise, Mario, 975-978  
 Deri, John J., 490-495  
 Dhorajwala, J., 664-669  
 Dilworth, Vickie, 940-946  
 DiMattio, Joseph, 903-906  
 Dixit, P.K., 302-309  
 Doberne, Leonard, 387-392, 829-835  
 Dodson, Leonard E., Jr., 465-470  
 Dollar, Laura A., 979-982  
 D'Onofrio, Felice, 1008-1012  
 Dons, Robert F., 896-902  
 Drash, Allan L., 279-284  
 Drury, P.L., 907-910

## E

Eckel, Robert H., 132-138  
 Egler, Joseph M., 965-969

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113

**AUTHOR INDEX 1981**

Ehrlich, Robert M., 710-717  
 Eichner, Harvey, 465-470  
 Eisenbarth, George S., 226-230, 887-889  
 Elde, Robert P., 168-171  
 Elliott, R.B., 26-29  
 Ellis, Steven, 903-906  
 El-Maghrabi, M. Raafat, 1062-1064  
 El-Sabban, Farouk, 89-92  
 Etzwiler, Donnell, 275-278  
 Evans, D.A. Price, 907-910

**F**

Faaiuso, S., 45-51  
 Farese, Robert V., 396-401  
 Farrar, P., 875-878  
 Felber, J.P., 1000-1007  
 Felig, Philip, 891-895  
 Field, J.B., 767-780  
 Fielden, H., 951-954  
 Fields, Rose M., 562-567  
 Filler, Robert M., 710-717  
 Finke, Edward H., 285-291  
 Fischer, E., 568-574  
 Fishbein, Howard A., 279-284  
 Flier, Jeffrey, S., 975-978  
 Fong, Henry K.W., 1022-1028  
 Franetzk, M., 1072-1075  
 Frank, Harrison J.L., 757-761  
 Freinkel, N., 56-63  
 Frigo, I., 302-309  
 Fujimoto, Wilfred Y., 446-450, 551-557  
 Fujita, Takuo, 188-191, 724-727

**G**

Galbo, H., 626-633  
 Galbraith, Gillian M.P., 235-241  
 Galbraith, Richard A., 235-241  
 Gamba, Silvia, 685-693  
 Gandy, Samuel E., 235-241  
 Ganguli, Supriya, 411-415  
 Gavin, Laurence A., 694-699  
 Gazdar, Adi, 226-230  
 Geisen, K., 1072-1075  
 Gelhrter, Thomas, 940-946  
 Geller, David M., 416-423  
 Genel, Myron, 891-895  
 Geoffrey, W.G. Sharp, 52-55  
 Gerber, Pietro P.G., 40-44, 865-867  
 Gerich, John E., 296-301, 377-381, 535-537, 728-734, 990-995  
 Ghafghazi, Taghi, 341-345  
 Ginsberg, Barry H., 773-780  
 Ginsberg, Henry, 739-745  
 Ginsberg, Leonard C., 393-395  
 Giugliano, Dario, 1008-1012  
 Gliemann, Jørgen, 1-8  
 Gluóth, Maria, 792-794  
 Goff, D.V., 951-954

Gold, Gerald, 77-82, 634-638  
 Goldman, Allen S., 965-969  
 Goldstein, Marc B., 781-787  
 Gonen, B., 875-878  
 Gordon, Phillip, 896-902  
 Gorn, Alan H., 670-677  
 Goto, Yasuo, 188-191  
 Gottheiner, Toby I., 929-934  
 Gøtzsche, O., 481-485  
 Gozes, Yehoshua, 314-316  
 Greene, Douglas A., 139-147, 967-974  
 Greene, K., 728-734  
 Greenfield, Michael S., 387-392, 829-835  
 Greider, M.H., 580-583  
 Grill, V., 56-63  
 Grodsky, Gerold M., 83-85, 634-638  
 Grouse, Lynette H., 168-171  
 Gundersen, H.J.G., 481-485  
 Guttman, R., 584-589

**H**

Haedt, L. Hallquist, 873-874  
 Hagmüller, G., 1072-1075  
 Halperin, Mitchell L., 781-787  
 Halter, Jeffrey B., 847-850  
 Hamburger, J., 1051-1057  
 Hampshire, Jennifer, 112-114  
 Handelsman, D.J., 459-464  
 Hannaford, Maureen C., 781-787  
 Hansen, Bruno, 1-8  
 Harris, Virginia, 358-361, 883-886  
 Harrison, Len C., 354-357  
 Haymond, Morey W., 377-381  
 Haynes, B., 887-889  
 Heaney, Thomas P., 824-828  
 Heininger, Diane, 9-13  
 Heldt, Anneliese, 83-85, 634-638  
 Hellouin de Minibus, Cl., 175-179  
 Hellsing, K., 19-25  
 Henrichs, I., 362-364  
 Hermansen, K., 203-210  
 Hidaka, Hideki, 402-406, 562-567  
 Higuchi Takeru, 1065-1067  
 Hilstead, J., 626-633  
 Hintz, Raymond L., 979-982  
 Hiraiwa, Yoshio, 440-445  
 Hofeldt, Fred, 465-470  
 Hoffman, L., 804-812  
 Hoffman, Phyllis L., 326-334  
 Holland, A., 362-364  
 Holst, Jens J., 1-18  
 Honey, R.N.M., 64-69  
 Horaguchi, Atsushi, 455-458  
 Hornes, Peter J., 504-509  
 Howard, Barbara V., 358-361, 402-406, 562-567  
 Huang, Shih-Wen, 873-874  
 Hummel, Katharine P., 1029-1034  
 Hynie, I., 584-589

**I**

Ideka, Hitoshi, 1045-1050  
 Ikeuchi, M., 446-450  
 Imamura, Toshinori, 440-445  
 Imura, Hiroo, 471-474  
 Irsigler, K., 1072-1075  
 Ishibashi, Fukashi, 402-406, 562-567  
 Ishibashi, Tatsuro, 601-606  
 Ishida, T., 767-780  
 Itoh, Mitsuyasu, 296-301, 728-734  
 Iwasaki, Makoto, 519-522  
 Iwatsuka, Hisahi, 1045-1050

**J**

Jackson, R., 887-889  
 Jacobson, D., 875-878  
 Jacot, E., 1000-1007  
 Jakobsen, Johannes, 797-803  
 Janah, S., 1068-1071  
 Janjic, Danilo, 960-966  
 Jaspas, J.B., 664-669, 767-780  
 Jenkins, D.J.A., 951-954  
 Jequier, E., 1000-1007  
 Jerntorp, Peter, 788-791  
 Johnson, Eugene M., Jr., 416-423  
 Johnson, R.L., 93-100  
 Jones, Robert L., 486-489  
 Joyner, W.L., 93-100

**K**

Kadowaki, Seizo, 188-191, 724-727  
 Kalkhoff, Ronald K., 545-550  
 Kamada, Akira, 1065-1067  
 Kanatsuna, Takahiro, 231-234  
 Kanazawa, Y., 446-450  
 Kasuga, Masato, 354-357  
 Kawato, Masanori, 440-445  
 Kawazu, S., 446-450  
 Keen, Harry, 818-823  
 Kelso, John M., 407-410  
 Kennedy, Allan Laurence, 115-118  
 Khokher, M.A., 1068-1071  
 Kientle, M. Galli, 644-649  
 Kikuchi, M., 446-450  
 Kilo, Charles, 326-334  
 Kilpatrick, M., 575-579  
 Kimsey, Gary, 235-241  
 Klein, Jean-Claude, 101-105  
 Klein, Steven H., 965-969  
 Klier, M., 362-364  
 Kobayashi, Masashi, 519-522  
 Kondo, Motoharu, 430-434  
 Kono, Norio, 346-353  
 Korányi, L., 792-794  
 Kosaka, K., 446-450  
 Kosmakos, Frank C., 402-406  
 Kowarski, A. Avinoam, 639-643  
 Kraemer, F., 387-392  
 Kramp, Robert C., 857-864

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113



# AUTHOR INDEX 1981

Krarup, T., 626-633  
Krausz, Yodphat, 960-966  
Kritz, H., 1072-1075  
Krzentowski, Georges, 983-989  
Kühl, Claus, 504-509  
Kuller, Lewis H., 279-284  
Kuret, Jeffrey, 9-13  
Kurtz, A.B., 650-655  
Kuwayama, Masamichi, 346-353  
Kuzuya, Hideshi, 471-474

## L

Lacroix, Marcel, 983-989  
Lacy, Paul E., 242-246, 285-291, 341-345  
Lacy, W.W., 180-187  
Laimins, M., 575-579  
Lake, W., 56-63  
Lampman, Richard M., 618-620  
Landsberg, Lewis, 219-225  
Lang, D.A., 435-439  
Lapolla, A., 705-709  
LaPorte, Ronald E., 279-284  
Larkins, Richard G., 256-260, 824-828, 939  
Larner, Joseph, 402-406  
Larson, Ronald E., 396-401  
Lauritsen, Keld B., 504-509  
Lederman, Michael M., 119-121  
Lee, Stanley M., 106-111  
Lefebvre, Pierre J., 851-856, 983-989  
Leiter, Edward H., 30-39, 662, 1029-1034  
Lemaignan, Hervé, 101-105  
Leontire, Andrea, 923-928  
Leonmark, Åke, 231-234, 424-429  
LeRoith, Derek, 70-76  
Lesniak, Maxine A., 70-76  
Lestrade, F., 175-179  
Lestrade, H., 175-179  
Levasseur, F., 175-179  
Levine, Lawrence, 163-167  
Lev-Ran, Arye, 996-999  
Licht, J. Hamilton, 510-518  
Like, Arthur A., 1058-1061  
Linde, Susanne, 1-8  
Lindgärde, F., 19-25  
Lindgren, Frank T., 132-138  
Lithell, H., 19-25  
Livingston, James N., 196-202  
Loria, Roger M., 89-92  
Louie, James, 127-131  
Lundqvist, G., 19-25  
Luyckx, Alfred, 851-856, 983-989

## M

McConnell, Thomas J., 718-723  
McCorkle, Kay, 358-361  
McCuskey, Robert S., 500-503  
McDaniel, Michael L., 341-345

McDonald, Roderick, 940-946  
McEvoy, Robert C., 813-816  
Mackay, Wilma, 656-663  
Mackes, K., 728-734  
Mackintosh, David, 818-823  
MacLaren, Noel K., 718-723  
McLaughlin, Judith V., 718-723  
McMahon, Francis A., 694-699  
McPherson, Janet, 372-376  
Madsbad, S., 626-633  
Maeder, E., 1000-1007  
Manabe, Shigeo, 1013-1021  
Mandarino, Lawrence J., 377-381, 990-995  
Mandel, T.E., 804-812  
Manning, Michele, 634-638  
Marchal, Georges, 851-856  
Margolis, Simeon, 639-643  
Marinan, Barbara, 292-295  
Marks, James F., 475-480  
Marshall, Stephen, 746-753  
Maruhama, Yoshisuke, 14-18  
Matschinsky, Franz M., 911-922, 923-928  
Matsukura, Shigeru, 188-191, 724-727  
Matsuo, Takao, 1045-1050  
Matta, S.G., 302-309  
Matthews, D.R., 435-439  
Mayhan, W.G., 93-100  
Mehl, Thomas D., 115-118  
Meistas, Mary T., 639-643  
Meneghel, A., 705-709  
Merimee, Thomas J., 115-118  
Merrell, Ronald C., 455-458  
Metz, Stewart A., 551-557  
Michael, Alfred F., 275-278, 843-846  
Miles, John M., 377-381  
Miller, Max, 656-663  
Miller, Ralph E., 40-44  
Milne, B., 45-51  
Milner, R.D.G., 271-274  
Minaker, Kenneth L., 219-225  
Mirouze, Jacques, 851-856  
Misiewicz, J.J., 951-954  
Moeller, Marie, 694-699  
Molinari, M., 705-709  
Moosa, A.R., 664-669  
Moriwara, Kazuyuki, 519-522  
Morosati, S., 644-649  
Mosora, Florentina, 983-989  
Moxley, Richard T., III, 106-202  
Mui, Mei Mei, 947-950  
Mullen, Yoko, 9-13

## N

Nakabayashi, Hajime, 440-445  
Nakamura, Yoshio, 430-434  
Nakano, Koji, 430-434  
Nathan, David M., 700-701  
Neely, Philip, 1062-1064  
Negri, A., 644-649  
Nimni, Marcel E., 670-677  
Nishihata, Toshiaki, 1065-1067  
Nosadini, R., 650-655

Nowlain, Robert, 634-638  
Noy, G., 650-655  
Nozawa, Masumi, 724-727  
Nygaard, E., 19-25

## O

Oh, Man S., 310-313  
Ohgaku, Seiji, 519-522  
Ohlin, Hans, 788-791  
Oie, Herbert, 226-230  
Oka, Tatsushi, 519-522  
Olefsky, Jerrold M., 148-162, 523-529, 596-600, 746-753, 979-982  
Ong, Shu-Hui, 500-503  
Ono, Junko, 242-246  
Orchard, Trevor J., 279-284  
Orci, Lelio, 192-195, 879-882  
Østerby, R., 481-485  
Owen, Oliver E., 510-518  
Owerbach, David, 267-270

## P

Pace, Caroline S., 621-625, 836-842  
Palazzolo, Marjorie, 372-376  
Pallikarakis, Nicolas, 983-989  
Pallotta, Johanna, 219-225  
Palmer, John L., 700-701  
Papoz, Laure, 101-105, 175-179  
Paradise, Caroline, 486-489  
Pardridge, William M., 757-761  
Passariello, Nicola, 1008-1012  
Patsch, Wolfgang, 530-534  
Periman, Kusiel, 710-717  
Péterfy, F., 792-794  
Peterson, Charles M., 486-489  
Pettit, James R., 634-638  
Pfeiffer, E.F., 362-364  
Pham, Tan Chi, 851-856  
Phares, C.K., 93-100  
Phillips, Catherine, 30-39  
Pickup, John C., 818-823  
Pietri, Angel O., 883-886  
Pilkis, Simon J., 1062-1064  
Pirnay, Freddy, 983-989  
Poirier, R., 584-589  
Polak, J.M., 122-126  
Polonsky, K.S., 664-669, 767-780  
Porte, Daniel, Jr., 558-561, 847-850  
Pottick, Lorelle A., 196-202  
Pouplard, A., 1051-1057  
Poussier, Philippe, 296-301  
Preteble, K., 1072-1075  
Prince, Melvin J., 596-600  
Pugh, W., 664-669

## Q

Qvist, Rajes, 256-260

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

R

Rabkin, Ralph, 929-934  
 Rasio, Eugenio, 317-325  
 Raskin, Philip, 475-480  
 Rassi, N., 887-889  
 Ravazzola, Mariella, 192-195, 879-882  
 Rayfield, Elliot J., 739-745  
 Reach, Gérard, 296-301  
 Reaven, E.P., 77-82  
 Reaven, Gerald M., 77-82, 387-392, 496-499, 829-835  
 Recant, Lillian, 127-131  
 Redman, Robert S., 127-131  
 Regis, Giorgio, 684-693  
 Renold, Albert E., 40-44, 52-55, 865-867  
 Ribes, Gerard, 52-55  
 Rich, Stephen, 873-874  
 Riley, William J., 718-723  
 Rizza, Robert A., 377-381, 535-537, 990-995  
 Robbins, Mark S., 168-171  
 Robertson, R. Paul, 551-557  
 Rodman, Harvey M., 119-121  
 Rogers, Susan P., 935-939  
 Röjdmarm, S., 767-780  
 Rosenbloom, Arlan, 115-118  
 Rosenblum, William I., 89-92  
 Rosenfeld, Ron G., 979-982  
 Roth, Jesse, 70-76  
 Rouiller, Dominique, 735-738  
 Rowe, John W., 219-225  
 Rozovski, S. Jaime, 678-684  
 Rubenstein, Arthur H., 231-234, 767-780, 979-982  
 Ruderman, Neil B., 678-684  
 Rudolf, Mary C.J., 891-895  
 Rushakoff, Robert J., 545-550  
 Rushforth, Norman, 656-663  
 Rutter, William J., 267-270  
 Ryan, Janice, 896-902  
 Rytting, J. Howard, 1065-1067

S

Sabir, Mohammad A., 396-401  
 Sacca, Luigi, 1008-1012  
 Sagara, Hosaku, 440-445  
 Sagel, J., 575-579  
 Sai, P., 1051-1057  
 Sakato, Shunichi, 440-445  
 Sakurai, Hideo, 471-474  
 Saltin, B., 19-25  
 Santeusano, Fausto, 607-612  
 Santiago, Julio V., 868-872  
 Santinga, John T., 618-620  
 Sapor, Daniel G., 510-518  
 Sar, Madhabananda, 382-386  
 Sarantis, Kosmas, 1058-1061  
 Sargeant, Daniel T., 868-872  
 Sarson, D.L., 951-954  
 Sato, Gordon H., 1022-1028

Sausse, André, 296-301  
 Savage, Peter J., 618-620  
 Searce, Richard M., 226-230  
 Scharp, C.R., 580-583  
 Scharp, D.W., 580-583  
 Schechter, Geraldine P., 127-131  
 Schiffman, Gerald, 119-121  
 Schmidt, Robert E., 416-423  
 Schneider, Barbara B., 279  
 Schnider, Stuart, 656-663  
 Schonfeld, Gustav, 530-534, 875-878  
 Schorry, Elizabeth, 940-946  
 Schultz, Julie A., 226-230  
 Schulz, Bernd, 829-835  
 Schusdzarra, Volker, 362-364, 735-738  
 Schwartz, Stanley S., 139-147  
 Segre, Giorgio, 685-693  
 Seino, Susumu, 471-474  
 Seino, Yasuo, 188-191  
 Seino, Yutaka, 471-474, 724-727  
 Selawry, Helena P., 947-950  
 Serjeantson, S., 26-29  
 Service, F. John, 377-381  
 Sessa, A., 644-649  
 Sestoft, L., 626-633  
 Seta, Takashi, 440-445  
 Sgambato, Saverio, 1008-1012  
 Shackelford, Annelie, 465-470  
 Shah, Jayendra H., 539-544  
 Sharp, Geoffrey W.G., 754-756, 960-966  
 Sherwin, Robert S., 891-895  
 Shigeta, Yukio, 519-522  
 Shino, Akio, 71, 1072-1075  
 Shows, Thomas B., 267-270  
 Shulman, G.I., 180-187  
 Sidenius, Per, 797-803  
 Siegel, Eberhard G., 52-55  
 Siegre, Eberhard G., 960-966  
 Silberlicht, Ira, 292-295  
 Simon, Douglas, 30-39  
 Simon, Ido, 773-780  
 Singh, Harbhajan, 292-295  
 Sinha, Madhur K., 411-415  
 Sirtori, C.R., 644-649  
 Skau, Kenneth, 797-803  
 Slama, Gérard, 101-105  
 Smeltzer, James, 656-663  
 Smoake, Al, 372-376  
 Solomon, Solomon S., 372-376  
 Sonne, Ole, 1-8  
 Sorensen, Bonita J., 539-544  
 Sorenson, Robert L., 168-171  
 Spector, Arthur A., 773-780  
 Sperling, Mark A., 411-415  
 Spritz, Norton, 292-295  
 Stastny, Peter, 475-480  
 Stauber, William T., 500-503  
 Stefan, Yolande, 192-195  
 Steffes, Michael W., 424-429  
 Steiner, Donald F., 231-234  
 Steiner, Kurt E., 490-495  
 Sternthal, Elliot, 1058-1061  
 Stevens, Arthur L., 219-225  
 Stevens, Bernard, 539-544

Stojeba, P.C. 580-583  
 Streeten, David H.P., 335-340  
 Strom, Terry B., 314-316  
 Stumpf, Walter E., 382-386  
 Sunderlin, Frederick S., Jr., 335-340  
 Surma, Maria, 367-371  
 Suzuoki, Ziro, G71  
 Szabó, J., 792-794

T

Taborsky, Gerald J., Jr., 847-850  
 Takeda, Ryoyu, 440-445  
 Tamai, Irene Y., 407-410  
 Tamás, Gy., Jr., 792-794  
 Tamborlane, William V., 891-895  
 Taminato, Tomohiko, 188-191, 724-727  
 Tan, M.H., 702-704  
 Tanaka, Kenzo, 601-606  
 Tanigawa, Keiichiro, 471-474  
 Taniguchi, Yoshiaki, 601-606  
 Tarui, Seichiro, 346-353  
 Tarvin, John T., 836-842  
 Taylor, G., 718-723  
 Taylor, R.H., 951-954  
 Tchobrousky, Georges, 101-105  
 Tchou, Pat, 656-663  
 Theophilus, J., 26-29  
 Thomas, D., 584-589  
 Thomson, A.B.R., 247-255  
 Thurow, H., 1072-1075  
 Tiengo, A., 705-709  
 Tilton, Ronald G., 326-334  
 Timson, C.M., 122-126  
 Tingle, A., 584-589  
 Tobey, T., 387-392  
 Torella, Roberto, 1008-1012  
 Tornheim, Patricia A., 762-766  
 Török, Angela, 792-794  
 Trent, D.F., 64-69  
 Tric, Ph., 175-179  
 Trimble, Elisabeth R., 40-44, 865-867  
 Tronier, B., 626-633  
 Trus, Michael D., 911-922, 923-928  
 Tsai, Phoebe, 596-600  
 Tsai, Tan-Sheng, 929-934  
 Tsanakaws, J., 271-274  
 Tsuda, Kinsuke, 471-474  
 Turco, Gianluigi, 685-693  
 Turner, R.C., 435-439  
 Turtle, J.R., 459-464

U

Unger, Roger H., 358-361, 735-738, 879-882, 883-886  
 Urdanivia, Enrique, 367-371  
 Usher, Patricia, 975-978  
 Usukura, Noriomi, 440-445

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113

---

**AUTHOR INDEX 1981**

---

**V**

Valerio, A., 705-709  
 Valka, Beth, 940-946  
 Van Obberghen, Emmanuel, 354-357  
 Van Zile, J., 575-579  
 Verdonk, Carlos A., 377-381, 535-537  
 Vessby, B., 19-25  
 Viberti, Giancarlo, 818-823  
 Virella, G., 575-579

**W**

Wachslight-Rodbard, Helena, 896-902  
 Wada, Osamu, 1013-1021  
 Wagener, Diane K., 279-284  
 Wahl, Larry, 127-131  
 Wahl, Patricia W., 132-138  
 Wahren, J., 1000-1007

Waldeck, Nancy, 465-470  
 Wasada, Taro, 358-361  
 Watson-Wright, W.M., 702-704  
 Weill, Victoria A., 911-922  
 Weir, G.C., 64-69, 590-595  
 Weiss, Roy E., 670-677  
 Wells, David, 797-803  
 Weringer, Eldora J., 407-410  
 West, R., 584-589  
 Whitehouse, S., 45-51  
 Whitlow, Margaret G., 868-872  
 Wiedenkeller, Dayna E., 754-756  
 Wilkins, J., 584-589  
 Williams, Phillip E., 180-187, 490-495  
 Williamson, Joseph R., 326-334  
 Wilson, G.L., 451-454  
 Winegrad, Albert I., 139-147, 967-974  
 Wirdnam, P.K., 271-274  
 Wollheim, Claes B., 40-44, 52-55, 960-966  
 Wyse, Beatrice M., 393-395

**Y**

Yalow, Rosalyn S., 265-266  
 Yamada, Kenneth M., 354-357  
 Yanase, Eimei, 440-445  
 Yoshida, Toshihide, 430-434  
 Yoshimitsu, Kohei, 440-445  
 Young, James B., 219-225  
 Younoszai, R., 302-309

**Z**

Zadik, Zvi, 639-643  
 Zadunaisky, José A., 172-174, 903-906  
 Zawalich, Kathleen C., 923-928  
 Zawalich, Walter S., 911-922  
 Zimmet, P., 26-29, 45-51  
 Zitron, Ian M., 242-246  
 Zmachinski, C.J., 590-595  
 Zyznar, Edward S., 883-886

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

---

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113